***CURRICULUM VITAE***

**CHRISTOPHER MARK FILLEY**

**PROFESSOR OF NEUROLOGY AND PSYCHIATRY**

**UNIVERSITY OF COLORADO SCHOOL OF MEDICINE**

**PROFESSIONAL ADDRESS**

Behavioral Neurology Section

Department of Neurology

12631 East 17th Avenue

P.O. Box 6511

Mail Stop B185

Aurora, Colorado 80045

Phone: 303 724-2046

Fax: 303 724-4082

Email: christopher.filley@cuanschutz.edu

**EDUCATION**

**B.A.** **-** Williams College, 1969-1973; Major: English

**Post-baccalaureate studies** **-** University of Colorado at Denver, 1973-1975

**M.D.** **-** Johns Hopkins University, 1975-1979

**Internal Medicine** **Internship -** University of Connecticut Affiliated Hospitals, 1979-1980

**Neurology Residency** **-** University of Colorado Affiliated Hospitals, 1980-1983

**Behavioral Neurology Fellowship -** Aphasia/Neurobehavior Unit, Boston Veterans Administration Hospital, 1983-1984

**ACADEMIC AND HOSPITAL APPOINTMENTS**

Instructor, Department of Neurology, University of Colorado School of Medicine, Denver, Colorado, 1984-1985

Assistant Professor, Department of Neurology, University of Colorado School of Medicine, Denver, Colorado, 1985-1991

Consulting Neurologist and Electroencephalographer, Fort Logan Mental Health Center, Denver, Colorado, 1984-1989

Consulting Neurologist, Colorado State Hospital, Pueblo, Colorado, 1984-2006

Member, Section on Behavioral Neurology, American Academy of Neurology, 1984-present

Member, Section on Geriatric Neurology, American Academy of Neurology, 1984-present

Consulting Neurologist, Cognitive Rehabilitation Program, University of Colorado Health Sciences Center, 1986-1988

Assistant Professor, Department of Psychiatry, University of Colorado School of Medicine, Denver, Colorado, 1987-1991

Founder and Director, Neurobehavior Clinic, University Hospital, Denver, Colorado, 1987 -present

Member, Board of Directors, Alzheimer's Disease and Related Disorders Association, Metro Denver Chapter, 1988-1990

Behavioral Neurology Fellowship Director, Department of Neurology, University of Colorado School of Medicine, 1988-1997

Staff Neurologist, Denver Veterans Administration Medical Center, Denver, Colorado, 1989-2010

Founder and Director, Behavioral Neurology Section, Department of Neurology, University of Colorado School of Medicine, 1991-present

Associate Professor, Department of Neurology, University of Colorado School of Medicine, Denver, Colorado, 1991-1997

Associate Professor, Department of Psychiatry, University of Colorado School of Medicine, 1991-1997

Adjunct Associate Professor, Department of Psychology, University of Denver, 1995-1997

Neuropsychiatry Fellowship Director, Department of Neurology, University of Colorado School of Medicine, 1996-2005

Professor, Department of Neurology, University of Colorado School of Medicine, Denver, Colorado, 1997-present

Professor, Department of Psychiatry, University of Colorado School of Medicine, Denver, Colorado, 1997-present

Adjunct Professor, Department of Psychology, University of Denver, 1997-present

Consulting Neurologist, University of Colorado Multiple Sclerosis Center, 1997-present

Clinical Neurosciences Course Director, University of Colorado School of Medicine, 2004-2006

Director, Neurology Residency Program, University of Colorado School of Medicine, 2001-2003

Member, Association of University Professors of Neurology, 2001-2003

Electroencephalographer, Colorado Mental Health Institute at Pueblo, 2004-2006

Director, Medical Student Education, Department of Neurology, University of Colorado School of Medicine, 2004-2010

Clinical Neurosciences Course Director, University of Colorado School of Medicine, 2004-2006

Nervous System Block Committee, University of Colorado School of Medicine, 2004-2006

Neurology Clerkship Block Director, University of Colorado School of Medicine, 2004-2010

Consultant, National Jewish Medical and Research Center, 2004-2013

Consultant, Mental Illness Research, Education, and Clinical Center (MIRECC), Denver Veterans Affairs Medical Center, 2005-2017

Director, University of Colorado Alzheimer’s Disease and Cognition Center, 2006-2013

Chief, Neurology Service, Denver Veterans Affairs Medical Center, 2010-2017

Member, Center for Neuroscience, University of Colorado School of Medicine, 2011-present

Co-Leader, Clinical Core, University of Colorado Alzheimer’s and Cognition Center, 2013-present

Research Physician, University of Colorado Alzheimer’s and Cognition Center, 2015-present

Senior Scientific Advisor, Marcus Institute for Brain Health, 2017-present

**HONORS, SPECIAL RECOGNITIONS, AND AWARDS**

Bachelor of Arts *Cum Laude*, Williams College, 1973

Bachelor of Arts with Honors in English, Williams College, 1973

Member, Physicians for Social Responsibility, Affiliate of the International Physicians for the Prevention of Nuclear War, awarded the Nobel Peace Prize, 1985

Outstanding Teacher Award, Department of Neurology, University of Colorado School of Medicine, 1991

Co-recipient, Cottle Award for Basic Scientific Research, American Rhinologic Society, 1991

American Neurological Association, 1995

Fellow, American Academy of Neurology, 1998

Best Doctors in America, 1996-1997, 1998-1999, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013, 2014, 2015-2016, 2017-2018, 2019-2020

Who's Who in Medicine and Healthcare, 1997-1998, 1999-2000, 2000-2001, 2001-2002, 2002-2003, 2004-2005, 2006-2007, 2009-2010, 2011-2012

Who's Who in the West, 1998-1999, 2000-2001, 2001-2002

Who's Who in America, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2012, 2013, 2014, 2015, 2016

Who's Who in the World, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2008, 2015, 2016, 2018, 2019, 2020, 2021

Who's Who in Science and Engineering, 2002-2003, 2004, 2005, 2006-2007, 2008-2009

Excellence in Medical Student Teaching Award, Department of Neurology, University of Colorado School of Medicine, 1997-1998

Excellence in Medical Student Teaching Award, Department of Neurology, University of Colorado School of Medicine, 1998

Outstanding Clinical Teacher Award, 3rd Year Class, University of Colorado School of Medicine, 2001-2002

America’s Top Doctors (Castle Connolly), 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023

America’s Top Doctors (US News and World Report), Top 1% of US Neurologists, 2011, 2012

Who’s Who in Medical Science Education, 2005

America’s Top Physicians, 2004-2005, 2006

Excellence in Teaching Award, Class of 2007, University of Colorado School of Medicine, 2005

Colorado’s Top Doctors, Core Magazine, 2007

Outstanding Teacher Award, Department of Neurology, University of Colorado School of Medicine, 2009-2010

Excellence in Clinical Teaching, Third Year Class, University of Colorado School of Medicine, 2010-2011

Outstanding Faculty Recognition, University of Colorado Housestaff Association, 2012

Fellow, American Neurological Association, 2013

ICARE Award, Denver Veterans Affairs Medical Center, 2017

Service Award for 30 years of service to the United States Government, Denver Veterans Affairs Medical Center, 2017

Flag Presentation for 28 years of service to the Denver Veterans Affairs Medical Center, 2017

Albert Nelson Marquis Lifetime Achievement Award for being listed in Marquis Who’s Who publication for 20 or more years, 2017

Member, Physicians for Social Responsibility, Affiliate of the International Campaign to Abolish Nuclear Weapons, awarded the Nobel Peace Prize, 2017

Who's Who in Medicine Higher Education, 2019

5280 Magazine Top Doctor, 2019

Colorado Magazine Top Doctor, 2021

Expertscape World Expert in the White Matter, recognizing the top 0.1% of scholars writing about White Matter over the past 10 years, 2021.

Section Editor for Behavioral Neurology, Encyclopedia of the Neurological Sciences, 3rd Edition, 2022

Senior Guest Associate Editor for Frontiers in Neurology Research Topic “White Matter Dementia: Neuropathological and Neuropsychological Underpinnings and State of the Art Diagnosis Methods and Treatments,” 2022

Fellow, American Neuropsychiatric Association, 2023

Best Scientists in the field of Neuroscience ranking of #1408 in the United States and #3039 in the world, Research.com. 2023

Founding Member, University of Colorado School of Medicine Faculty Club, 2023

**MEMBERSHIP IN PROFESSIONAL ORGANIZATIONS**

American Academy of Neurology, 1984-present

Society for Behavioral and Cognitive Neurology, 1984-present

Colorado Neurological Society, 1985-present

International Neuropsychological Society, 1986-present

American Neurological Association, 1995-present

American Neuropsychiatric Association, 2016-present

**MAJOR COMMITTEES AND SERVICE RESPONSIBILITIES**

**Local**

Search Committee for Neuropsychology Director, Department of Psychiatry, 1986-1988

Neurology Cost Center Committee, 1988-2000

Neurology Cost Center Committee Chair, 1997-2000

Chair, Medical and Scientific Advisory Committee, Alzheimer's Disease and Related Disorders Association, Metro Denver Chapter, 1988-1990

Medical and Scientific Advisory Committee, Alzheimer's Association, Metro Denver Chapter, 1988-2013

Member, Board of Directors, Alzheimer’s Association, Metro Denver Chapter, 1988-1990

Medical School Admissions Committee, 1989-1996

Graduate Medical Education Committee, 1990-1991, 2001-2003

Department of Neurology Promotions Committee, 1991-present

Technical Standards for Medical School Admissions Committee, 1993-1996

Health Committee, Denver Foundation, 1995-1998

School of Medicine Faculty Senate, 1995-1996

Search Committee for Physical Medicine and Rehabilitation Chair, 1997

Medical School Promotions and Tenure Committee, 1997-2000

Given Biomedical Institute Steering Committee, 1997-2007

Graduate Medical Education Committee, 2001-2003

Board of Directors, Given Biomedical Institute, 2007-2011

Steering Committee for the 19th, 20th, and 21st Annual Education Symposia of the Colorado Alzheimer’s Association, 2007-2008, 2008-2009, 2009-2010

Clinical Competency Committee for Neurology Resident Evaluation, 2010-2018

Search Committee for Director of Alzheimer’s Disease Research, 2011

Search Committee for Clinical Director of Alzheimer’s Disease Research, 2011

Member, Executive Committee, Rocky Mountain Alzheimer’s Disease Center, 2013-present

Chair Department Promotions Committee for Victoria S. Pelak, MD, 2014

Co-Organizer, with Sharon N. Poisson, MD, of 2015 Stroke and Behavioral Neurology CME Conference, University of Colorado School of Medicine, October 3, 2015

Intradepartmental Neurology Grant Review Committee, 2016-2020

Chair, Departmental Promotions Committee for Jonathan H. Woodcock, MD, 2016

Chair, Departmental Promotions Committee for James P. Kelly, MD, 2017

Chair, Departmental Promotions Committee for Benzi M. Kluger, MD, 2017

Chair, Search Committee for Medical Director of the Marcus Institute for Brain Health, 2019

Chair, Post-Tenure Review Committee for Huntington Potter, PhD, 2022

**National**

Publications Committee, American Academy of Neurology, 1991-1993

Subcommittee on Education for Non-Neurologists, American Academy of Neurology, 1997-1999

Co-chair, Platform Session on Behavioral Neurology, 57th Annual Meeting of the American Academy of Neurology, 2002

Program Committee, American Neuropsychiatric Association, 2002-2006

National Institute on Drug Abuse Special Emphasis Panel ZDA1 EXL-T (04), Neuroimaging the Effects of Drug Abuse on the Development of the Central Nervous System, 2003

Co-chair, Platform Session on Aging and Dementia, 57th Annual Meeting of the American Academy of Neurology, 2005

National Institute on Aging, Reverse Site Visit for 2 UO1 AGO10483-16, Alzheimer’s Disease Cooperative Studies (ADCS), 2006

Co-chair, Platform Session on Aging and Dementia, 58th Annual Meeting of the American Academy of Neurology, 2006

Co-chair, Platform Session on Aging and Dementia, 59th Annual Meeting of the American Academy of Neurology, 2007

Moderator, Platform Session on Behavioral Neurology, Aging, and Dementia, 71st Annual Meeting of the American Academy of Neurology, 2019

Ad Hoc Committee Member to consider the promotion of Bradley C. Dickerson, MD to Professor of Neurology at Harvard Medical School, 2020

Session Chair, Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 31st Annual Meeting of the American Neuropsychiatric Association, Virtual meeting, 2021

Session Chair, Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 32nd Annual Meeting of the American Neuropsychiatric Association, Virtual meeting, 2022

Session Chair, Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Workshop, in Association with the 32nd Annual Meeting of the American Neuropsychiatric Association, Boston, MA, 2023

**International**

Co-organizer, with James P. Kelly, M.D., of the Annual Aspen Neurobehavior Conference, Aspen, Colorado, 1995, 1996, 1997, 1998, 1999

Program Committee, 25th Annual Meeting of the International Neuropsychological Society, 1997

Chair, Platform session on Neuroimaging, 25th Annual Meeting of the International Neuropsychological Society, 1997

Member-at-Large, Board of Governors, International Neuropsychological Society, 2008-2011

Consulting Editor, Journal of the International Neuropsychological Society, 2014-2023

Chair, Invited Symposium, “Norman Geschwind and the Lasting Influence of Disconnection.” 43rd Annual Meeting of the International Neuropsychological Society, Denver, Colorado, 2015

**LICENSURE AND BOARD CERTIFICATION**

State of Colorado, Practice of Medicine, 1980

Diplomate in Neurology, American Board of Psychiatry and Neurology, 1984

Diplomate in Behavioral Neurology and Neuropsychiatry, United Council for Neurologic Subspecialties, 2006, Recertification, 2016, Recertification, 2020

**REVIEW AND REFEREE WORK**

VA Grant Reviewer

Raven Press

International Journal of Psychiatry in Medicine

Neurology

Neuropsychiatry, Neuropsychology, and Behavioral Neurology

Journal of the Neurological Sciences

The MIT Press

Child Abuse and Neglect

School Psychology Review

Archives of Neurology

Journal of Neuropsychiatry and Clinical Neurosciences

Acta Neurologica Scandinavica

Journal of the International Neuropsychological Society

Collegium Anthropologicum (Zagreb, Croatia)

Editorial Board, Clinical Neuropharmacology, 1998-2003

Oxford University Press

Annals of Neurology

Alzheimer’s Association

National Institutes of Health Peer Reviewer

Schweppe Foundation

The New England Journal of Medicine

Neuropsychology

Multiple Sclerosis

Medical Science Monitor

American Neuropsychiatric Association Annual Meeting Abstract Reviewer

American Academy of Neurology Annual Meeting Abstract Reviewer

Neuroscience and Biobehavioral Reviews

Cognitive and Behavioral Neurology

Annals of General Psychiatry

Cerebral Cortex

Expert Review of Neurotherapeutics

European Journal of Neurology

Pennsylvania Department of Health

Journal of Cerebral Blood Flow and Metabolism

Cortex

The American Journal of Psychiatry

Neuroimage

Arthritis & Rheumatism

Current Alzheimer Research

Mount Sinai Journal of Medicine

Neurology Today

Neurocase

Neurology: Clinical Practice

Neuropsychology Review

Neurological Sciences

Journal of the American Medical Association

Guilford Press

Journal of Head Trauma Rehabilitation

Cambridge University Press

American Journal of Neuroradiology

Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association

Acta Neuropathologica

Movement Disorders

Future Neurology

Developmental Medicine and Child Neurology

Neurobiology of Aging

Neuroimage: Clinical

The Journal of Alzheimer’s Disease

Texas Alzheimer’s Research and Care Consortium

Neurotoxicology

Journal of Neurology, Neurosurgery, and Psychiatry

Colorado Clinical and Translational Sciences Institute

Brain Imaging and Behavior

Journal of Addiction Medicine

Clinical Case Reports

Multiple Sclerosis and Related Disorders

Frontiers in Aging Neuroscience

European Journal of Paediatric Neurology

Science

Clinical Neurology and Neurosurgery

Scientific Reports

BMC Neuroscience

Editorial Board, Journal of the International Neuropsychological Society, 2011-present

Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences, 2017-present

**INVITED LECTURES, PRESENTATIONS, AND VISITING PROFESSORSHIPS**

1. 5/1/81 - "Central and Peripheral Neurotoxicity of Podophyllin Resin." Poster Presentation, American Academy of Neurology Annual Meeting, Toronto, Ontario
2. 2/6/85 - "Behavioral Neurology," Lecture, Colorado Society of Clinical Neurologists, Denver, Colorado
3. 10/4/85 - "Closed Head Injury in Childhood: Neurobehavioral Outcome," Poster Presentation, American Neurological Association Annual Meeting, Philadelphia, Pennsylvania
4. 7/11/86 - "Neurologic Aspects of Elderly Psychiatric Patients," Lecture, Colorado Mental Health Conference, Frisco, Colorado
5. 9/19/86 - "Does a Neurologist Make a Difference?" Lecture, Colorado Mental Health Conference, Breckenridge, Colorado
6. 3/20/87 - "Update on Alzheimer's Disease," Lecture, St. Anthony's Hospital, Denver, Colorado
7. 4/7/87 - "MRI Findings in Normal Aging and Alzheimer's Disease," Poster Presentation, American Academy of Neurology Annual Meeting, New York, New York
8. 8/7/87 - "Alzheimer's Disease," Employee Grand Rounds, University of Colorado Health Sciences Center, Denver, Colorado
9. 11/25/87 - "The Frontal Lobes and Emotional Behavior," Lecture, Swedish Hospital, Denver, Colorado
10. 1/16/88 - "Diagnosis of Alzheimer's Disease," Lecture, Alzheimer's Disease and Related Disorders Association, Denver, Colorado
11. 3/24/88 - "Pharmacologic Treatment of Neurobehavioral Disorders," Lecture, Denver Neurobehavior Study Group, Denver, Colorado
12. 3/31/88 - "Alzheimer's Disease," Panel Discussion, Senior Showcase, KRMA, Channel 6, Denver, Colorado
13. 4/20/88 - "Alzheimer's Disease," Teleconference to 3-state region, Denver, Colorado
14. 7/29/88 - "Pharmacologic Treatment of Alzheimer's Disease," Lecture, Beth Israel Pavilion, Denver, Colorado
15. 9/15/88 - "Medical and Social Issues in Dementing Illness," Lecture, UCHSC, Denver, Colorado
16. 10/13/88 - "Alzheimer's Disease," Panel Discussion, UCHSC, Denver, Colorado
17. 10/17/88 - "Causes of Alzheimer's Disease, Diagnosis, Treatment, and Current Research," Lecture, Alzheimer's Disease Subcommittee, State Capitol Building, Denver, Colorado
18. 4/15/89 - "Neuropsychological Impairment in Chronic Toluene Abuse," Platform Presentation, American Academy of Neurology Annual Meeting, Chicago, Illinois
19. 6/22/90 - "Closed Head Injury," Lecture, Vail Neuropsychiatry Conference, Vail, Colorado
20. 11/2/90 - "The Latest in Alzheimer's Disease Research," Lecture, Alzheimer's Symposium, Denver, Colorado
21. 1/31/91 - "Seizure Disorders," Lecture, Psychiatry Service, Fitzsimons Hospital, Denver, Colorado
22. 6/9/91 - "Current Status of Alzheimer's Disease Research," Alzheimer's Association Region 10 Meeting, Copper Mountain, Colorado
23. 6/14/91 - "Therapeutic Implications of Brain Regeneration After Mild Head Injury," Mild Head Injury Conference, Colorado Head Injury Foundation, Copper Mountain, Colorado
24. 11/2/91 - "Alzheimer's Disease," Panel Discussion, Senior Showcase, KRMA, Channel 6, Denver, Colorado
25. 11/16/91 - "Alzheimer's Research: Hope for the Future," Lecture, Alzheimer's Association, Denver, Colorado
26. 12/10/91 - "Psychiatry/Neurology Interface," Lecture, Bethesda Hospital, Denver, Colorado
27. 1/9/92 - "Psychiatric Aspects of Seizure Disorders," Psychiatry Service, Lecture, Fitzsimons Hospital, Aurora, Colorado
28. 1/21/92 - "Recent Advances in Alzheimer's Disease," Lecture, Lutheran Hospital, Denver, Colorado
29. 4/10/92 - "Humanities, Science, and the Life of the Mind," Lecture, First Annual Williams College Neuroscience Conference, Williamstown, Massachusetts
30. 5/7/92 - "Neurobehavioral and Pathologic Features of Frontotemporal Degeneration," Platform Presentation, American Academy of Neurology Annual Meeting, San Diego, California
31. 10/20/92 - "Alzheimer's Disease," Lecture, University Opinion Series, University Hospital, Denver, Colorado
32. 6/23/93 - "Clinical Implications of Programmed Cell Death," Lecture, Second Berkshire Neuroscience Symposium, Pittsfield, Massachusetts
33. 10/6/93 - "Is There Really Any Hope for an Effective Treatment for Alzheimer's Disease?" Lecture, Colorado Society of Clinical Neurologists, Denver, Colorado
34. 11/6/94 - "Neuroimaging and Electrodiagnostic Testing in Mild Traumatic Brain Injury." Lecture and Panel Discussion, 13th National Head Injury Foundation Symposium, Chicago, Illinois
35. 12/2/94 - "Education, the Brain, and Alzheimer's Disease." Lecture, Montrose Memorial Hospital, Montrose, Colorado
36. 3/29/95 - Opening remarks, First Annual Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
37. 4/2/95 - Closing comments, First Annual Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
38. 5/11/95 - "Education and Cognitive Function in Alzheimer's Disease." Poster Presentation, American Academy of Neurology Annual Meeting, Seattle, Washington
39. 9/8/95 - "Prevention and Treatment of Cognitive Decline." Lecture, University of Colorado School of Medicine Conference on Alzheimer's Disease and Dementia: The Primary Practitioner's Role, Denver, Colorado
40. 12/14/95 - "Neurobehavioral Aspects of Cerebral White Matter." Lecture, Denver University Neuroscience Research Group, Denver, Colorado
41. 3/9/96 - Opening remarks, Second Annual Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
42. 3/13/96 - Closing comments, Second Annual Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
43. 4/16/96 - "Alzheimer's Disease: Now What?" Lecture, St. Mary's Hospital, Grand Junction, Colorado
44. 5/3/96 - "Treatment of Alzheimer's Disease." Lecture, Colorado Neuropsychological Society, Colorado Springs, Colorado
45. 1/18/97 - "Research Update in Alzheimer's Disease." Lecture, Alzheimer's Association, Denver, Colorado
46. 3/10/97 - "The Aging Brain: Use It or Lose It." Lecture, University Seniors Association, Museum of Natural History, Denver, Colorado
47. 4/2/97 - Opening remarks, Third Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
48. 4/6/97 - Closing comments, Third Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
49. 4/3/97 - "The Emerging Crisis of Alzheimer's Disease," Lecture, Given Institute, Aspen, Colorado
50. 2/1/98 - "Erotomania After Aneurysmal Subarachnoid Hemorrhage: Neuropsychiatric Aspects." Poster Presentation, American Neuropsychiatric Association Annual Meeting, Honolulu, Hawaii
51. 4/5/98 - Opening remarks. Fourth Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
52. 4/9/98 - Closing comments, Fourth Aspen Neurobehavior Conference, Given Institute, Aspen, Colorado
53. 8/9/98 - "A User's Guide to the Aging Brain." Lecture, Aspen Health and Fitness Symposium, Given Institute, Aspen, Colorado
54. 9/10/98 - "Subcortical Dementia." Geriatric Grand Rounds, Denver VA Medical Center
55. 9/13/98 - "Diagnosis and Management of Dementia." Lecture, Neurology Update for the Primary Care Practitioner, University of Colorado School of Medicine, Given Institute, Aspen, Colorado
56. 3/27/99 - Opening remarks. Fifth Annual Aspen Neurobehavior Conference, Aspen Meadows, Aspen, Colorado
57. 3/31/99 - Closing comments. Fifth Annual Aspen Neurobehavior Conference, Aspen Meadows, Aspen, Colorado
58. 5/4/99 - "Alzheimer's Disease and Related Dementias: The Latest Information." 10th Annual Rocky Mountain Alzheimer's Association Symposium, Denver, Colorado
59. 6/18/99 - "Progress in Alzheimer's Disease." Lecture, 45th Annual Family Practice Review, University of Colorado School of Medicine, Estes Park, Colorado
60. 7/10/99 - "Treatments for Dementia." Neurology Update for the Neurologist, University of Colorado School of Medicine, Given Institute, Aspen, Colorado
61. 7/14/99 - "New Treatments for Dementia." 35th Annual Internal Medicine Program, University of Colorado School of Medicine, Estes Park, Colorado
62. 10/1/99 - "Neuropsychological and Psychosocial Impact of Multiple Sclerosis." International Symposium on Multiple Sclerosis: The Impact of the Disease, Vienna, Austria
63. 10/15/99 - "Brain-Behavior Relationships: An Overview." Gundersen Lutheran Hospital, La Crosse, Wisconsin
64. 10/15/99 - "Neurobehavioral Sequelae of Traumatic Brain Injury." Gundersen Lutheran Hospital, La Crosse, Wisconsin
65. 11/13/99 - "Behavioral Neurology for Neuropsychologists." Workshop Presentation for the 19th Annual National Academy of Neuropsychology Conference, San Antonio, Texas (Co-sponsored by the American Academy of Neurology)
66. 4/20/01 - "Drug Trials in Alzheimer's Disease." Seminar for Neuroscience students, Regis University, Denver, Colorado
67. 5/15/01 - "Diagnosis of Alzheimer's Disease and Other Dementias." 12th Annual Symposium of the Rocky Mountain Alzheimer's Association, Aurora, Colorado
68. 7/13/01 - "New Treatment Considerations for the Demented Patient." 37th Annual Internal Medicine Program, University of Colorado School of Medicine, Estes Park, Colorado
69. 9/2/01 - "The Behavioral Neurology of White Matter." Neurology Grand Rounds, Northwestern University Medical School, Chicago, Illinois
70. 10/14/01 - "Toxic Leukoencephalopathy." Poster Presentation, 1st Annual Coleman Institute for Cognitive Disabilities Conference, Given Institute, Aspen, Colorado
71. 3/10/02 - “Geriatric Treatment Center: A Contemporary Model for Collaboration between Psychiatry and Neurology.” Poster Presentation, American Neuropsychiatric Association Annual Meeting, San Diego, California
72. 5/7/02 - “Clinical Trials in Alzheimer’s Disease.” 2002 Annual Symposium of the Rocky Mountain Alzheimer’s Association, Aurora, Colorado
73. 5/29/02 - “Toxic Leukoencephalopathy.” Lecture, 30th Annual Meeting of the American Academy of Physician’s Assistants, Hynes Center, Boston, Massachusetts
74. 9/25/02 - “Traumatic Brain Injury and Violence.” Lecture, Colorado Mental Health Institute at Pueblo, Pueblo, Colorado
75. 9/27/02 - “Cognitive Disorders: The State of the Science.” Lecture, 2nd Annual Coleman Institute for Cognitive Disabilities Conference, Boulder, Colorado
76. 10/12/02 - “The Behavioral Neurology of White Matter.” Workshop Presentation for the 22nd Annual National Academy of Neuropsychology Conference, Miami, Florida
77. 4/2/03 **- “**Colorado Surveillance Program for Chronic Wasting Disease Transmission to Humans: Two Negative Cases.” Poster Presentation, American Academy of Neurology Annual Meeting, Honolulu, Hawaii
78. 10/7/03 - “White Matter Dementia.” Lecture for University of Colorado Health Sciences Center Course “Neurodegenerative Dementias: Diagnosis and Treatment in Contemporary Practice,” Denver, Colorado
79. 11/7/03 - “The Early Diagnosis of Dementia.” Lecture to Medical Staff at Community Hospital, Grand Junction, Colorado
80. 12/3/03 - “White Matter Dementia.” Lecture to the Colorado Society of Clinical Neurologists, Denver, Colorado
81. 1/9/04 - “Clinicopathological Conference.” Department of Medicine, Denver Veterans Affairs Medical Center, Denver, Colorado
82. 4/12/04 - “Creativity – A Neurological Perspective.” University of Colorado Health Sciences Center, Arts in Medicine Series
83. 4/22/04 - “Neurobehavioral Presentations of Brain Neoplasms.” Colorado Christian University, Lakewood, Colorado
84. 8/20/04 - “White Matter and Behavioral Neurology.” White Matter in the Cognitive Neurosciences: Advances in Diffusion Tensor Imaging and Its Applications Workshop. New York Academy of Sciences, Manhattan, New York
85. 1/28/05 - “Creativity – A Neurological Perspective.” Lecture for the 35th Annual Colorado Psychiatric Society Mid-Winter Meeting, Englewood, Colorado
86. 2/2/05 - “White Matter and Human Behavior: A Clinical Approach.” Workshop for the 33rd Annual Meeting of the International Neuropsychological Society, St. Louis, Missouri
87. 6/10/05 – “Behavioral Neurology and White Matter: The Challenge of Brain Connectivity.” Department of Neurology Grand Rounds, University of Rochester Medical School, Rochester, New York
88. 9/23/05 – “White Matter Dementia.” Seminar for the Department of Psychology, University of Denver
89. 10/21/05 – “The Behavioral Neurology of White Matter: An Emerging Perspective.” Department of Neurology Grand Rounds, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire
90. 2/10/06 – “White Matter Disease and Cognition.” International Workshop on Myelin Imaging, Vancouver, BC, Canada
91. 3/31/06 – “The Neurology of Creativity.” Lecture for the series *Neuropsychiatry and the Mind* for the Denver Psychoanalytic Society, Denver, Colorado
92. 4/5/06 - "Primary Progressive Aphasia in a Bilingual Woman." Poster Presentation, American Academy of Neurology Annual Meeting, San Diego, California
93. 9/12/06 – “The Behavioral Neurology of White Matter: An Emerging Perspective.” Colorado Neuropsychological Society Fall Meeting, Denver, Colorado.
94. 9/23/06 – “Creativity and the Brain.” Keynote Address, Rocky Mountain Multiple Sclerosis Center Meeting on the Arts and Living with MS, Arvada Center for the Arts and Humanities, Arvada, Colorado
95. 10/20/06 – “Aging and Alzheimer’s Disease.” Interview for “Life Wise,” Rocky Mountain PBS, Denver, Colorado (aired 6 times in early 2007)
96. 10/24/06 – "Primary Progressive Aphasia in a Bilingual Woman." Poster Presentation, 6th Annual Coleman Institute for Cognitive Disabilities Conference, Broomfield, Colorado
97. 11/21/06 – “Alzheimer’s Disease Update.” Rural Health Clinical Grand Rounds, UCDHSC, Denver, Colorado
98. 12/7/06 – “Toluene Leukoencephalopathy.” Panel discussion at the 45th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, Florida
99. 1/18/07 – Introductory Comments for Ronald C. Petersen, Ph.D., M.D., Invited Speaker for the Hartford/Jahnigen Center of Excellence in Geriatrics Research Forum, co- sponsored by the University of Colorado Alzheimer’s Disease and Cognition Center, Denver, Colorado
100. 2/17/07 – “Neurobehavioral Aspects of White Matter.” Society for Behavioral and Cognitive Neurology Workshop, Tucson, Arizona
101. 2/20/07 – “Very Early Onset Alzheimer’s Disease: Is Genetic Testing Mandatory?” Poster Presentation, American Neuropsychiatric Association Annual Meeting, Tucson, Arizona
102. 2/20/07 – “Very Early Onset Alzheimer’s Disease: Is Genetic Testing Mandatory?” Hot Topics Presentation, American Neuropsychiatric Association Annual Meeting, Tucson, Arizona
103. 2/23/07 – Tour Guide Presentation on Art and the Brain for the Denver Art Museum Hamilton Wing
104. 5/2/07 **– “**Visual perception of rotating 3D virtual objects presented in an immersive virtual reality environment in Alzheimer’s Disease, mild cognitive impairment, and normals.” Poster presentation. American Academy of Neurology Annual Meeting, Boston, Massachusetts
105. 5/5/07 – “Diseases of Cerebral White Matter.” Lecture for half-day course on Structure Function Correlations in Behavioral Neurology. American Academy of Neurology 59th Annual Meeting, Boston, Massachusetts
106. 10/24/07– “Very Early Onset Alzheimer’s Disease: Is Genetic Testing Mandatory?” Poster Presentation, 7th Annual Coleman Institute for Cognitive Disabilities Conference, Westminster, Colorado
107. 10/26/07 – “Neurological Perspectives on Art.” Tour of Denver Art Museum Hamilton Wing for Second Year Medical Students
108. 1/17/08 – “Accuracy of Dementia Diagnosis: 20 Year Experience of the Neurobehavior Clinic.” UCSOM Division of Geriatrics Grand Rounds
109. 3/3/08 – “The Value of the Clock Drawing Test in the Evaluation of Alzheimer’s Disease.” Poster Presentation, American Neuropsychiatric Association Annual Meeting, Savannah, Georgia
110. 4/7/08 – “White Matter and Cognition.” Presentation at the Conference on Systemic Lupus Erythematosus and Cognitive Dysfunction sponsored by the Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Medical College-Cornell University, New York, New York
111. 4/10/08 – “Mind, Brain, Neuroscience, and Society.” Presentation at Intersections II: Mind, Brain and Experience, at the Intersections of Philosophy, Science, and Medicine, Department of Philosophy, University of Colorado Denver, Denver, Colorado
112. 4/13/08 – “Diseases of Cerebral White Matter.” Lecture for half-day course on Structure Function Correlations in Behavioral Neurology. American Academy of Neurology 60th Annual Meeting, Chicago, Illinois
113. 7/4/08 – Discussant for Symposium at 30th International Neuropsychological Society Mid-Year Meeting, Buenos Aires, Argentina: “Neuropsychological Aspects of Multiple Sclerosis in Children and Adults”
114. 1/15/09 – “White Matter Microstructure and Cognition in Non-Neuropsychiatric Systemic Lupus Erythematosus.” Poster Presentation, Conference on Executive Function sponsored by the Institute of Cognitive Science, University of Colorado Boulder, Millennium Harvest House Hotel, Boulder, Colorado
115. 2/11/09 – “The Behavioral Neurology of White Matter.” Workshop for the 37th Annual Meeting of the International Neuropsychological Society, Atlanta, Georgia
116. 2/14/09 – “Neurologic Perspectives on White Matter.” (With Jeremy D. Schmahmann, James P. Kelly, and Eric E. Smith) Invited Symposium for the 37th Annual Meeting of the International Neuropsychological Society, Atlanta, Georgia.
117. 2/20/09 – “Update on the Neurobiology of Violence.” Invited lecture for the 20th Annual Meeting of the American Neuropsychiatric Association, San Antonio, Texas.
118. 2/20/09 – “When Cognitive Evaluation Does Not Disclose a Neurologic Disorder: Experience of a University Behavioral Neurology Clinic.” Poster Presentation, 20th Annual Meeting of the American Neuropsychiatric Association Annual Meeting, San Antonio, Texas
119. 2/23/09 – “White Matter and Behavioral Neurology.” Invited lecture for the Research Advisory Committee on Gulf War Veterans’ Illnesses, UT Southwestern, Dallas, Texas.
120. 4/6/09 – “Art and (Dis) Ability, Chuck Close – Close Up.” Lecture for The Arts in Medicine series of the Medical Humanities Program, University of Colorado Denver School of Medicine, Aurora, Colorado.
121. 6/25/09 – “Alzheimer’s Disease.” Lecture for University of Colorado Denver School of Medicine 56th Family Medicine Review, Estes Park, Colorado
122. 6/25/09 – “Case Studies in Dementia.” Workshop for University of Colorado Denver School of Medicine 56th Family Medicine Review, Estes Park, Colorado.
123. 7/15/09 – “Early Dementia: Clinical Features and Treatment Options.” Lecture for University of Colorado Denver School of Medicine 45th Annual Internal Medicine Program, Estes Park, Colorado
124. 10/30/09 – White Matter Dementia,” Seminar for Neuroscience Research Group, University of Denver Department of Psychology, Denver, Colorado.
125. 4/7/10 – “Cognitive Dysfunction and Cerebral White Matter in SLE.” Grand Rounds Presentation for Division of Rheumatology, Hospital for Special Surgery, Weill Medical College-Cornell University, New York, New York
126. 4/12/10 – “White Matter Dementia.” Lecture for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 62nd Annual Meeting, Toronto, Ontario
127. 10/19/10 – “Alzheimer’s Disease.” Lecture for Colorado Bioscience Association, Denver Museum of Nature and Science, Ricketson Auditorium
128. 1/13/11 – “Alzheimer’s Disease.” Lecture for Round Table International, Denver Country Club.
129. 3/25/11 – “Neuroimmunology.” Chair of Half-Day Course for the 22nd Annual Meeting of the American Neuropsychiatric Association, Denver, Colorado
130. 3/25/11 – “Neurobehavioral Sequelae of Neuroimmunologic Disease.” Lecture forthe 22nd Annual Meeting of the American Neuropsychiatric Association, Denver, Colorado
131. 4/16/11 – “White Matter Dementia.” Lecture for Half-Day Course for the 63rd Annual Meeting of the American Academy of Neurology, “Non-Alzheimer’s Dementia,” Honolulu, Hawaii
132. 9/9/11 – “The Neurobiology of Aggression and Violence”. Lecture for VISN 19 MIRECC 4th Annual TBI and Suicide Prevention Conference Traumatic Brain Injury, Aggression, and Self-Directed Violence, Denver, Colorado
133. 9/26/11 – “Advances in the Behavioral Neurology of White Matter.” Special Interest Group Presentation for the 136th Annual Meeting of the American Neurological Association, San Diego, California
134. 9/30/11 – “Information Processing Speed and White Matter Abnormalities in Non-neuropsychiatric SLE.” Poster Presentation. University of Colorado 2011 Annual Neuroscience Program Retreat, Keystone, Colorado.
135. 3/14/12 – “Alzheimer’s Disease Biomarkers: A Clinical Update.” Multidisciplinary Conference Series, UCSOM Department of Neurology, Aurora, Colorado
136. 4/4/12 – “Accuracy of Community-Acquired PET Scans in Dementia Diagnosis.” Poster Presentation, UCSOM Department of Neurology Research Retreat, Aurora, Colorado
137. 4/22/12 -“White Matter Dementia.” Lecture for Half-Day Course for the 64th Annual Meeting of the American Academy of Neurology, “Non-Alzheimer’s Dementia,” New Orleans, Louisiana
138. 6/1/12 – “Beyond Corticocentrism: A Deeper View of Cognition.” Department of Neurology Grand Rounds, University of California San Francisco, San Francisco, California.
139. 12/6/12 – “White Matter and Cognition: Past, Present, and Future.” Lecture for Neuroscience Students, Regis University, Denver, Colorado
140. 1/18/13 – “Neurobehavioral Sequelae of Solvent Abuse.” Lecture for Addiction Psychiatry Fellowship, Department of Psychiatry, University of Colorado School of Medicine, Denver Health Medical Center, Denver, Colorado
141. 3/22/13 -“White Matter and Dementia.” Lecture for Half-Day Course for the 65th Annual Meeting of the American Academy of Neurology, “Non-Alzheimer’s Dementia,” San Diego, California
142. 5/16/13 – “White Matter Dementia.” Neurology Grand Rounds, Albert Einstein Medical School, Montefiore Medical Center, Bronx, New York
143. 11/15/13 – “Neurobehavioral Sequelae of Solvent Abuse.” Lecture for Addiction Psychiatry Fellowship, Department of Psychiatry, University of Colorado School of Medicine, Denver Health Medical Center, Denver, Colorado
144. 4/27/14 -“White Matter and Dementia.” Lecture for Half-Day Course for the 66th Annual Meeting of the American Academy of Neurology, “Non-Alzheimer’s Dementia,” Philadelphia, Pennsylvania
145. 5/1/14 – “White Matter Disease and Cognitive Impairment in FMRI Premutation Carriers.” Poster Presentation, 66th American Academy of Neurology Annual Meeting, Philadelphia, Pennsylvania
146. 6/6/14 – “White Matter Dementia.” Lecture for Center for Brain Health, University of Texas Dallas, Dallas, Texas
147. 1/30/15 – “The Behavioral Neurology of White Matter: A New Concept.” Keynote address for the 38th Congress of the Groupe de Recherche sur la Maladie D’Alzheimer (GRAL), Neurologie Comportementale de la Substance Blanche. » Aix-Marseille Université, Marseille, France
148. 2/6/15 – ‘Disconnection and White Matter.” Lecture for Invited Symposium “Norman Geschwind and the Lasting Influence of Disconnection.” 43d Annual Meeting of the International Neuropsychological Society, Denver, Colorado, 2015.
149. 2/6/15 – ‘Disconnection and White Matter.” Lecture for Invited Symposium “Norman Geschwind and the Lasting Influence of Disconnection.” 43d Annual Meeting of the International Neuropsychological Society, Denver, Colorado, 2015.
150. 10/3/15 – “Vascular Dementia.” Lecture for 2015 Stroke and Behavioral Neurology CME Conference Center, Bruce Schroffel Conference Center, University of Colorado Hospital
151. 3/9/17 – “The Expanding Differential Diagnosis of Toxic Leukoencephalopathy. Platform presentation at the 28th Annual Meeting of the American Neuropsychiatric Association, Atlanta, Georgia
152. 3/22/17 – “White Matter Dementia,” Lecture for Neuropsychology Seminar, University of Colorado School of Medicine, Department of Neurosurgery, Aurora, Colorado
153. 5/18/17 – “White Matter Dementia.” Keynote Address for the 6th Annual Conference of the Alzheimer’s Association Conference, New Mexico Chapter, co-sponsored by the University of New Mexico Memory and Aging Center, Albuquerque, New Mexico
154. 5/18/17 – “White Matter Dementia - Clinical Implications.” Breakout session for the 6thAnnual Conference of the Alzheimer’s Association, New Mexico Chapter, co-sponsored by the University of New Mexico Memory and Aging Center, Albuquerque, New Mexico
155. 8/31/17 – “White Matter and Cognition: Making the Connection.” Lecture for Colorado Society of Clinical Neurologists, Denver, Colorado
156. 9/8/17 – Expert Panel Discussant, Michael K. Cooper Neuropsychiatry Conference “Frontotemporal Dementia.” Hyatt Regency Conference Center, Aurora, Colorado
157. 12/9/18 – Discussant for book-signing by Brad Bawmann for “Beagle on Board,” Tattered Cover Book Store, Denver, Colorado
158. 3/22/19 – “Social cognition and white matter: a clinical perspective.” Poster presentation. 30th Annual Meeting of the American Neuropsychiatric Association, Chicago, Illinois.
159. 11/22/19 – “Music and Brain Health.” Presentation with Renée Fleming for the “Music and the Mind” Symposium sponsored by the Arts and Humanities in Healthcare Program, Anschutz Medical Campus, Aurora, Colorado
160. 4/21/20 – “Music and the Brain.” Lecture (via Zoom) for University of Denver Piano Pedagogy Program, Denver, Colorado
161. 6/3/20 – “Morality and the Brain: Systematic Review of Lesional Causes of Immorality.” Poster presentation (via Zoom) at the 10th Annual Department of Neurology Research Retreat, University of Colorado School of Medicine, Aurora, Colorado
162. 6/25/20 – Co-Presentation, with Gayla Elliott, MA, ATR and James P. Kelly, MD, of the Marcus Institute for Brain Health Art Therapy Program to Karen Pence, 2nd Lady of the United States, Krugman Conference Hall, Anschutz Medical Campus, Aurora, Colorado
163. 10/30/20 – “Frontotemporal Dementia and Social Cognition: The Role of White Matter.” Virtual Lecture for Michael K. Cooper Educational Series in Frontotemporal Dementia, University of Colorado School of Medicine, Aurora, Colorado
164. 11/19/20 – “Brain Health.” Virtual Keynote Address for Advances in Neurology 2020, Fort Collins, Colorado
165. 2/23/21 - “White Matter and Cognition: Making the Connection.” Virtual Seminar for Colorado State University Neuroscience Group, Fort Collins, Colorado, organized by Aga Burzynska, PhD
166. 3/17/21 - “Introduction and Case Presentation.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 31st Annual Meeting of the American Neuropsychiatric Association, Virtual meeting
167. 3/17/21 -“White Matter Disorders: New Perspectives in Treatment and Recovery.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 31st Annual Meeting of the American Neuropsychiatric Association, Virtual meeting
168. 5/15/21 - “Biomarkers in Traumatic Brain Injury.” Lecture for the 9th Annual Symposium of the Sports Neuropsychology Society, Virtual Meeting
169. 5/18/21 – “Music and the Brain.” Lecture for Inaugural Conference of the National Association of Medical Orchestras, Virtual meeting
170. 3/16/22 - “Case Presentation.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 32nd Annual Meeting of the American Neuropsychiatric Association, Virtual meeting
171. 3/16/22 -“Social Cognition, White Matter, and the Neural Basis of Morality.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Pre-Meeting Workshop, in Association with the 32nd Annual Meeting of the American Neuropsychiatric Association, Virtual meeting
172. 3/17/22 – “White Matter, Behavioral Neurology, and the Influence of Corticocentrism.” Poster presentation at the 32nd Annual Meeting of the American Neuropsychiatric Association, Virtual meeting
173. 6/1/23 – “White Matter, Behavioral Neurology, and the Influence of Corticocentrism.” Poster presentation at the 12nd Annual Department of Neurology research Retreat, University of Colorado School of Medicine, Aurora, Colorado.
174. 12/11/22 – Interview for KDVR Channel 31 News on Concussion and Chronic Traumatic Encephalopathy
175. 3/16/22 – “Introduction and Case Presentation.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Workshop, in Association with the 33rd Annual Meeting of the American Neuropsychiatric Association, Boston, MA
176. 3/16/22 -“Social Cognition, White Matter, and the Neural Basis of Morality.**”** Daniel I. Kaufer Behavioral Neurology & Neuropsychiatry Workshop, in Association with the 33rd Annual Meeting of the American Neuropsychiatric Association, Boston, MA
177. 3/21/23 – “Vascular White Matter Disease and Cognition.” Plenary lecture for Rotman Research Institute, University of Toronto, Virtual Conference on Aging & the Brain: The Vascular System and the Aging Brain.
178. 5/31/23 – “White Matter Disconnection in Acquired Criminality.” Poster presentation at the 13th Annual Department of Neurology Research Retreat, University of Colorado School of Medicine, Aurora, Colorado.
179. 6/7/23 – “Scholarship in Behavioral Neurology.” Seminar for University of Colorado Department of Neurology Behavioral Neurology Section, Building 400, University of Colorado Anschutz Medical Campus.

**TEACHING RECORD**

Clinic and Inpatient Attending, University of Colorado Hospital, Aurora, Colorado, 1984-present

Clinic and Inpatient Attending, Denver Veterans Affairs Medical Center, 1989-2017

Department Grand Rounds in Neurology, Psychiatry, and Geriatrics, University of Colorado School of Medicine, 1985-present (as requested)

Pre-Clinical Neuroscience Curriculum, University of Colorado School of Medicine, Selected Topics, 1985-present)

Clinical Neurology Clerkship Lecture Series, University of Colorado School of Medicine, Selected Topics, 1985-2004 (as requested)

Lectures and Seminars for Resident Education in Departments of Psychiatry and Medicine, University of Colorado School of Medicine, Selected Topics, 1985-2004

Continuing Medical Education Lectures in Internal Medicine and Family Practice Review Courses, University of Colorado School of Medicine, 1985-present (as requested)

Neuropsychiatry Conferences, Fort Logan Mental Health Center, Denver, Colorado, Selected Topics, 1985-1989

Course Director and Lecturer, "Neuropsychiatry," Colorado State Hospital, Pueblo, Colorado, 1985-1986

Neuropsychiatry Grand Rounds, Colorado State Hospital, Pueblo, Colorado, Selected Topics, 1986-1997

Neurobehavior Seminars to Neurology residents, fellows, and students, University of Colorado School of Medicine, 1988-present

Lecturer, "Acquired Cognitive Disorders in Adults," Department of Communication Disorders and Speech Sciences, University of Colorado at Boulder, 1997

Clinical Neurosciences Course Director, University of Colorado School of Medicine, 2004-2010

Nervous System Block Committee, University of Colorado School of Medicine, 2004-2010

Neurology Clerkship Block Director, University of Colorado School of Medicine, 2004-2010

Lecturer and Mentor, Marcus Institute for Brain Health, 2017-present

**Behavioral Neurology Fellows**

1. James P. Kelly, MD, 1988-1989
2. Lawrence A. Meredith, MD, 1993-1995
3. C. Alan Anderson, MD, 1995-1996
4. James F. Paskavitz, MD, 1996-1997

**Neuropsychiatry Fellows**

1. David B. Arciniegas, MD, 1996-1999
2. Susie N. Harris, MD, 2002-2003
3. Kristin M. Brousseau, DO, 2003-2004
4. Benjamin S. Alderfer, MD, 2004-2005

**Behavioral Neurology & Neuropsychiatry Fellows**

1. Timothy J. Oster, MD, 2006-2008
2. Hal S. Wortzel, MD, 2006-2008
3. Peter J. Wagner, MD, 2009-2010
4. Eryn A. Lonnquist, MD, 2012-2014
5. Michael J. Persenaire, MD, 2015-2016
6. Samantha K. Holden, MD, 2015-2017
7. Brice V. McConnell, MD, PhD, 2016-2017
8. Justin Persson, MD, 2017-2018
9. James (“Trey”) Bateman, MD, MPH, 2017-2018
10. Justin Otis, MD, 2018-2019
11. Isaiah Kletenik, MD, 2019- 2020
12. Jakob Mrozewski, MD, 2019-2020
13. Zachary A. Macchi, MD, 2019-2021
14. Tara C. Carlisle, MD, PhD, 2020-2022
15. Austin Momii, MD, 2022-2023
16. Morgan Farley, MD, 2023-2024

**Medical Student Research Trainees**

1. Michael Reardon, 1994, 1995
2. Jason Persoff, 1994
3. Jodi Meis, 1998
4. Meredith Kenfield, 2008, 2009, 2010
5. Alison Hixon, 2016
6. Katherine Belanger, 2018, 2019

**Mentored Student Activity Program Students**

1. Meredith Kenfield, 2007-2011
2. Cameron Schubert, 2017

**Foundations of Doctoring Thesis Year Student**

1. Alison Hixon, 2017

**Undergraduate Student Trainees**

1. Sheena Shipley, UCD, 2010 - 2012
2. Zane Sternberg, UCD, 2012
3. Christina Coughlan, PhD, 2021 - present
4. Sama Kareem, 2023

**Advanced Practice Providers**

1. Carol Hennessy, NP, 2013 - 2017
2. Christen Epstein, NP, 2014 - 2018
3. Julie Berk, NP, 2014 - 2015
4. Patrice McMoon, PA, 2016 - 2019
5. Kelly Finch, NP, 2017 - present
6. Lindsey Schulz, PA, 2021 – 2023
7. Avani Shah, PA, 2023 - present

**Neuropsychology Fellow**

1. Luis D. Medina, PhD, 2017 - 2018

**Marcus Institute for Brain Health Personnel**

1. Catharine Johnston-Brooks, PhD, 2017 - present
2. Jeffrey R. Hebert, PhD, PT, 2017 - present
3. Mark Babcock, MSW, LCSW, 2017 - present
4. Hilary Diefenbach, MA, CCC-SLP, 2017 - present
5. Gayla Elliott, MA, ATR, 2018 - present

**GRANT SUPPORT**

Investigator, Sandoz Protocol for Randomized Controlled Trial of Hydergine-LC in patients with Alzheimer's Disease, 1985-1987

Co-Investigator, "Neurological Sequelae of Chronic Toluene Inhalation Abuse," National Institute on Drug Abuse, 1988-1989

Investigator, Miles Protocol for Randomized Controlled Trial of Nimodipine in patients with Alzheimer's Disease, 1989-1992

Research Award, Metro Denver Chapter, Alzheimer's Association, 1990

Principal Investigator, "Cytochrome Oxidase Deficiency in Alzheimer's Disease." Project 2 of National Institute on Aging Program Project Grant AGO9417, entitled "Metabolic Studies in Dementia, Aging, and Demyelination." 2/1/91-3/31/94

Co-Investigator, "Differential Diagnosis in Learning Disabilities: Brain Morphology in Reading Disabled Twins," National Institute of Child Health and Human Development, 12/1/91-11/30/00

Research Award, Fraternal Order of Eagles, Pueblo, Colorado, 1993

Co-Investigator, "Neurologic AIDS Research Consortium," National Institute of Neurological Disorders and Stroke, 12/1/93-6/30/95

Investigator, Bayer protocol for Randomized Controlled Trial of Metrifonate in patients with Alzheimer's Disease, 1994-1999

Investigator, Forest protocol for Randomized Controlled Trial of Physostigmine-LA in patients with Alzheimer's Disease, 1994-1999

Investigator, Eisai/Pfizer protocol for Randomized Controlled Trial of Donepezil in patients with Alzheimer's Disease, 1996-1998

Investigator, Bayer protocol for Randomized Controlled Trial of Metrifonate in patients with Alzheimer's Disease, 1998-1999

Investigator, Novartis protocol for Randomized Controlled Trial of Rivastigmine in patients with Alzheimer's Disease, 1997-1999

Investigator, Fujisawa protocol for Randomized Controlled Trial of FK960 in patients with Alzheimer's Disease, 1999- 2000

Investigator, Lilly protocol for Randomized Controlled Trial of Olanzapine versus Risperidone for psychosis in patients with Alzheimer's Disease, 1999-2001

Investigator, Janssen protocol for Randomized Controlled Trial of Galantamine in patients with Alzheimer's Disease, 2001-2003

Investigator, Eisai protocol for Randomized Controlled Trial of Donepezil in patients with Vascular Dementia, 2001-2004

Investigator, Forest protocol for Randomized Controlled Trial of Memantine in patients with Alzheimer's Disease, 2002-2004

Investigator, Forest protocol for Randomized Controlled Trial of Memantine in conjunction with standard pharmacotherapy in patients with Alzheimer’s Disease, 2002-2004

Investigator, Forest protocol for Randomized Controlled Trial of Neramexane in patients with Alzheimer’s Disease, 2003-2004

Investigator, Forest protocol for Randomized Controlled Trial of Neramexane in conjunction with standard pharmacotherapy in patients with Alzheimer’s Disease, 2003-2004

Research Award, L.W. Frohlich Charitable Trust, 2002-2003

Co-Investigator, “Virtual Reality Kinetopsic 3D Recognition in AD and aMCI.” National Institute on Aging, 7/1/04-6/30/07

Co-Investigator, “MRI/MRS Correlates of Cognitive Function in SLE.” National Institute for Arthritis, Musculoskeletal and Skin Disease, 8/15/04-6/30/09

Co-Investigator, “Immune Correlates of Cognitive Function in SLE.” National Institute for Arthritis, Musculoskeletal and Skin Disease, 7/1/05-6/30/09

Co-Investigator, “Traumatic Brain Injury and Post Traumatic Stress Disorder: The Exploration of a Combined Syndrome.” Colorado Traumatic Brain Injury Trust Fund, 7/1/05-6/30/06

Co-Investigator, “Development of Visual Perception Tests for Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease Using Computer-Based Graphics and Virtual Reality Applications.” National Institute on Aging, 7/1/07-10/11/13

Co-Investigator, “Virtual Reality Assessment of Visuospatial Disorientation in Alzheimer’s Disease.” Alzheimer’s Association, 5/1/06-10/25/13

Principal Investigator, University of Colorado Alzheimer’s Disease and Cognition Center (ADCC), University of Colorado School of Medicine, 7/1/06-1/31/14

Co-Investigator, “Functional and Neuroanatomical MRI Correlates of Spatial and Other Cognitive Domain Changes Associated with Testosterone Supplementation in Healthy Older Men.” University of Colorado ADCC Pilot Project, 7/1/06-12/31/10

Co-Investigator, “Diffusion Tensor Imaging (DTI) in Male Carriers of Fragile X.” University of Colorado ADCC Pilot Project, 2/1/09-1/31/14

Co-Investigator, “Standard of Care Longitudinal Database for the Study of Alzheimer’s Disease, Dementia, and Down Syndrome.” University of Colorado Alzheimer’s and Cognition Center, University of Colorado School of Medicine, 5/1/15-present

Co-Investigator, “Longitudinal Biomarker and Clinical Phenotyping Study.” University of Colorado Alzheimer’s and Cognition Center, University of Colorado School of Medicine, 1/1/16-present

Co-Investigator, “An Investigation of Immune Biology and Alzheimer’s Disease-Related Biomarkers in Asymptomatic, Late-Life Mild TBI.”  Convergence Science Research Award, Department of Defense, 9/1/19-8/31/24

Co-Investigator, “Ocular Motor Function and Related Brain Morphology, Network and Circuitry Metrics in Military Veterans with Mild Traumatic Brain Injury.” Department of Defense, 9/15/22-11/22/25

Co-Investigator, “Emotional Dyscontrol in Veterans with Extended History of Mild Traumatic Brain Injury and Upright Balance Control and Auditory Sensory Processing Contributions.” Department of Defense, 9/15/22-11/22/25

**BIBLIOGRAPHY**

**Journal Articles (Peer-Reviewed)**

1. **Filley CM**, Graff-Radford NR, Lacy JR, Heitner M, Earnest MP. Neurologic manifestations of podophyllin toxicity. Neurology 1982;32:308-311.
2. **Filley CM**, Stumpf DA, Wilkening GN. Visual hallucinations in a blind epileptic. Neuro-ophthalmology 1983;3:167-170.
3. **Filley CM**, Sternberg PE, Norenberg MD. Neuromyelitis optica in the elderly. Arch Neurol 1984;41:670-673.
4. Lacy JR, **Filley CM**, Earnest MP, Graff-Radford NR. Cerebral infarction and hemorrhage in young and middle-aged adults. West J Med 1984;141:329-334.
5. **Filley CM**, Brownell HH, Albert ML. Education provides no protection against Alzheimer's Disease. Neurology 1985;35:1781-1784.
6. Hormes JT, **Filley CM**, Rosenberg NL. Neurologic sequelae of chronic solvent vapor abuse. Neurology 1986;36:698-702.
7. **Filley CM**, Kelly J, Heaton RK. Neuropsychologic features of early- and late-onset Alzheimer's Disease. Arch Neurol 1986;43:574-576.
8. **Filley CM**, Cranberg LD, Alexander MP, Hart EJ. Neurobehavioral outcome after closed head injury in childhood and adolescence. Arch Neurol 1987;44:194-198.
9. **Filley CM**, Kobayashi J, Heaton RK. Wechsler intelligence scale profiles, the cholinergic system, and Alzheimer's Disease. J Clin Exp Neuropsychol 1987;9:180-186.
10. **Filley CM**, Jarvis PE. Delayed reduplicative paramnesia. Neurology 1987;37:701-703.
11. Cranberg LD, **Filley CM**, Hart EJ, Alexander MP. Acquired aphasia in childhood: clinical and CT investigations. Neurology 1987;37:1165-1172.
12. Earnest MP, Reller LB, **Filley CM**, Grek AJ. Neurocysticercosis in the United States: thirty-five cases and a review. Rev Infect Dis 1987;9:961-979.
13. Rosenberg NL, Kleinschmidt-DeMasters BK, Davis KA, Dreisbach JN, Hormes JT, **Filley CM**. Toluene abuse causes diffuse central nervous system white matter changes. Ann Neurol 1988;23:611-614.
14. Rosenberg NL, Spitz MC, **Filley CM**, Davis KA, Schaumburg HH. Central nervous system effects of chronic toluene abuse-clinical, brainstem evoked response and magnetic resonance imaging studies. Neurotoxicol Teratol 1988;10:489-495.
15. **Filley CM**. Diagnosis of Alzheimer's Disease. Colorado Med 1988;85:48-49.
16. Burkhardt CR, **Filley CM**, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy body disease and progressive dementia. Neurology 1988;38:1520-1528.
17. Franklin GM, Heaton RK, Nelson LM, **Filley CM**, Seibert C. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology 1988;38:1826-1829.
18. **Filley CM**, Franklin GM, Heaton RK, Rosenberg NL. White matter dementia: clinical disorders and implications. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:239-254.
19. **Filley CM**, Heaton RK, Nelson LM, Burks JS, Franklin GM. A comparison of dementia in Alzheimer's Disease and multiple sclerosis. Arch Neurol 1989;46:157-161.
20. Franklin GM, Nelson LM, **Filley CM**, Heaton RK. Cognitive loss in multiple sclerosis: case reports and review of the literature. Arch Neurol 1989;46:162-167.
21. **Filley CM**, Davis KA, Schmitz SP, Stears JC, Heaton RK, Kelly J, Culig KM, Scherzinger AL. Neuropsychological performance and magnetic resonance imaging in Alzheimer's Disease and normal aging. Neuropsychiatry Neuropsychol Behav Neurol 1989;2:81-91.
22. Thompson LL, **Filley CM**. A pilot study of neuropsychological rehabilitation. J Neurol Rehab 1989;3:117-127.
23. **Filley CM**, Heaton RK, Rosenberg NL. White matter dementia in chronic toluene abuse. Neurology 1990;40:532-534.
24. Parker WD, **Filley CM**, Parks J. Cytochrome oxidase deficiency in Alzheimer's Disease. Neurology 1990;40:1302-1303.
25. Thompson TL, **Filley CM**, Mitchell WD, Culig KM, LoVerde M, Byyny RL. Lack of efficacy of Hydergine in patients with Alzheimer's Disease. New Engl J Med 1990;323:445- 448.
26. Hormes JT, Austin JH, James G, Smith DB, Ens G, Solomons C, **Filley CM**. Toward an optimal "anti-platelet" dose of aspirin: preliminary observations. J Stroke Cerebrovascular Dis 1991;1:27-35.
27. Kelly JP, Nichols JS, **Filley CM**, Lillehei KO, Rubinstein D, Kleinschmidt-DeMasters BK. Concussion in sports: guidelines for the prevention of catastrophic outcome. J Am Med Assoc 1991;266:2867-2869.
28. Kleinschmidt-DeMasters BK, **Filley CM**, Bitter MA. Central nervous system angiocentric, angiodestructive T-cell lymphoma (lymphomatoid granulomatosis). Surg Neurol 1992; 37:130-137.
29. **Filley CM**, Gross KF. Psychosis with cerebral white matter disease. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:119-125.
30. Jafek BW, Eller PM, Johnson EW, Chapman MM, Moran DT, **Filley CM**. Ultrastructural changes of the olfactory epithelium in Alzheimer's Disease. Am J Rhinology 1992;6:219-225.
31. Burkhardt C, Kelly JP, Lim Y-H, **Filley CM**, Parker WD. Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1993;33:512-517.
32. **Filley CM**, Kelly JP. Alcohol- and drug-related neurotoxicity. Curr Opin Neurol Neurosurg 1993;6:443-447.
33. **Filley CM**, Cullum CM. Early detection of fronto-temporal degeneration by clinical evaluation. Arch Clin Neuropsychol 1993;8:359-367.
34. **Filley CM**, Kleinschmidt-DeMasters BK, Gross KF. Non-Alzheimer fronto-temporal degenerative dementia. A neurobehavioral and pathologic study. Clin Neuropathol 1994;13:109-116.
35. Parker WD, Mahr NJ, **Filley CM**, Parks JK, Hughes D, Young DA, Cullum CM. Reduced platelet cytochrome *c* oxidase activity in Alzheimer's disease. Neurology 1994;44:1086-1089.
36. Parker WD, Parks J, **Filley CM**, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology 1994;44:1090-1096.
37. **Filley CM**, Cullum CM. Attention and vigilance functions in normal aging. Appl Neuropsychol 1994;1:29-32.
38. Cullum CM, **Filley** CM, Kozora E. Episodic memory function in advanced aging and early Alzheimer's Disease. J Int Neuropsychol Soc 1995;1:100-103.
39. **Filley CM**. Alzheimer's Disease: it's irreversible but not untreatable. Geriatrics 1995;50:18-23.
40. Paskavitz JF, Anderson CA, **Filley CM**, Kleinschmidt-DeMasters BK, Tyler KL. Acute arcuate fiber demyelinating encephalopathy following Epstein-Barr virus infection. Ann Neurol 1995;38:127-131.
41. **Filley CM**, Kleinschmidt-DeMasters BK. Neurobehavioral presentations of brain neoplasms. West J Med 1995;163:19-25.
42. **Filley CM**. Neuropsychiatric features of Lewy Body Disease. Brain Cogn 1995;28:229-239.
43. **Filley CM**. Behavioural manifestations of multiple sclerosis. Int MSJ 1996;2:91-97.
44. **Filley CM**, Chapman MM, Dubovsky SL. Ethical concerns in the use of palliative drug treatment for Alzheimer's Disease. J Neuropsychiatry Clin Neurosci 1996;8:202-205.
45. Maddrey AM, Cullum CM, Weiner MF, **Filley CM**. Premorbid intelligence estimation and level of dementia in Alzheimer's Disease. J Int Neuropsychol Soc 1996;2:551-555.
46. **Filley CM**, Cullum CM. Education and cognitive function in Alzheimer's Disease. Neuropsychiatry Neuropsychol Behav Neurol 1997;10:48-51.
47. **Filley CM**. Alzheimer's Disease in women. Am J Obstet Gynecol 1997;176:1-7.
48. Giacino JT, Zasler ND, Katz DI, Kelly JP, Rosenberg JH, **Filley CM**. Development of practice guidelines for assessment and management of the vegetative and minimally conscious states. J Head Trauma Rehab 1997;12:79-89.
49. Anderson CA, Rubinstein D, **Filley CM**, Stears JC. MR enhancing brain lesions in methanol intoxication. J Comp Assist Tomogr 1997;21:834-836.
50. Anderson CA, Wilkening GN, **Filley CM**, Reardon MS, Kleinschmidt-DeMasters BK. Neurobehavioral outcome in pediatric craniopharyngioma. Pediatr Neurosurg 1997;26:255-260.
51. **Filley CM**. The behavioral neurology of cerebral white matter. Neurology 1998;50:1535-1540.
52. Anderson CA, Camp J, **Filley CM**. Erotomania after aneurysmal subarachnoid hemorrhage: case report and literature review. J Neuropsychiatry Clin Neurosci 1998;10:330-337.
53. **Filley CM**. White matter lacunar infarcts and cognition: new observations. Neurology Network Commentary 1998;2288-291.
54. Arciniegas DB, Adler LE, Topkoff J, Cawthra E, **Filley CM**, Reite ML. Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Injury 1999;13:1-13.
55. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (**Filley CM**, consultant). The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
56. Yee AS, Simon JH, Anderson CA, Sze C-I, **Filley CM**. Diffusion-weighted MRI of right hemisphere dysfunction in Creutzfeldt-Jakob disease. Neurology 1999;52:1514-1515.
57. **Filley CM**, Thompson LL, Sze C-I, Simon JH, Paskavitz JF, Kleinschmidt-DeMasters BK. White matter dementia in CADASIL. J Neurol Sci 1999;163:163-167.
58. Kaltreider LB, Cullum CM, Lacritz LH, Brewer K, **Filley CM**. Brief recall tasks and memory assessment in Alzheimer's Disease. Appl Neuropsychol 1999;6:165-169.
59. Arciniegas DB, **Filley CM**. Implications of impaired cognition for organ transplant candidacy. Curr Opin Organ Transplantation 1999;4:168-172.
60. **Filley CM**, Young DA, Reardon MS, Wilkening GN. Frontal lobe lesions and executive dysfunction in children. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:156-160.
61. Kozora E, **Filley CM**, Julian LJ, Cullum CM. Cognitive functioning in patients with chronic obstructive pulmonary disease and mild hypoxemia compared with patients with mild Alzheimer Disease and normal controls. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:178-183.
62. Ramsberger G, Miyake A, Menn L, Reilly K, **Filley CM**. Selective preservation of geographical and numeric information in a patient with severe anomia. Aphasiology 1999;8:625-645.
63. Pennington BF, Filipek PA, Lefly D, Churchwell J, Kennedy DN, Simon JS, **Filley CM**, Galaburda A, Alarcon M, DeFries JC. Brain morphometry in reading-disabled twins. Neurology 1999;53:723-729.
64. **Filley CM**. Toxic leukoencephalopathy. Clin Neuropharmacol 1999;22:249-260.
65. Anderson CA, Sandberg E, **Filley CM**, Harris SL, Tyler KL. One and one-half syndrome with supranuclear facial weakness: magnetic resonance imaging localization. Arch Neurol 1999;56:1509-1511.
66. Bolla L, **Filley CM**, Palmer RM. Dementia DDx: office diagnosis of the four major types of dementia. Geriatrics 2000;55:34-46.
67. Pennington BF, Filipek PA, Lefly DA, Chhabildas N, Kennedy DN, Simon JS, **Filley CM**, Galaburda A, DeFries JC. A twin MRI study of size variations in human brain. J Cog Neurosci 2000;12:223-232.
68. Arciniegas D, Olincy A, Topkoff J, McRae K, Cawthra E, **Filley CM**, Reite M, Adler LE. Impaired auditory gating and P50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2000;12:77-85.
69. Sze C-I, Bi H, Kleinschmidt-DeMasters BK, **Filley CM**, Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's Disease brains. J Neurol Sci 2000;175:81-90.
70. **Filley CM**. Clinical neurology and executive dysfunction. Semin Speech Lang 2000;21:95-108.
71. Sze C-I, Bi H, Kleinschmidt-DeMasters BK, **Filley CM**, Martin LJ. *N*-methyl-D-aspartate receptor subunits and their phosphorylation status are altered selectively in Alzheimer's Disease. J Neurol Sci 2001;182:151-159.
72. **Filley CM**, Price BH, Nell V, Antoinette T, Morgan AJ, Bresnahan JF, Pincus JH, Gelbort MM, Weissberg M, Kelly JP. Toward an understanding of violence: neurobehavioral aspects of unwarranted physical aggression. Aspen Neurobehavioral Conference Consensus statement. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:1-14.
73. **Filley CM**, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001;345:425-432.
74. Harris JG, **Filley CM**. CADASIL: Neuropsychological findings in three generations of an affected family. J Int Neuropsychol Soc 2001;7:768-774.
75. **Filley CM**. The neuroanatomy of attention. Semin Speech Lang 2002;23:89-98.
76. **Filley CM**. Drug treatment of Alzheimer's Disease. Primary Care Case Reviews 2002;5:77-85.
77. **Filley CM**, Arciniegas DB, Wood GV, Anderson CA, Cheney E, Dygert CR, Summerall L, Goos RB. Geriatric treatment center: a contemporary model for collaboration between psychiatry and neurology. J Neuropsychiatry Clin Neurosci 2002;14:344-350.
78. Rollins YD, **Filley CM**, McNutt JT, Chalal S, Kleinschmidt-DeMasters BK. Fulminant ascending paralysis as a delayed sequela of diethylene glycol (Sterno) ingestion. Neurology 2002;59:1460-1463.
79. Hall DA, Anderson CA, **Filley CM**, Newcombe J, Hughes RL. A French accent after corpus callosum infarct. Neurology 2003;60:1551-1552.
80. **Filley CM**, Kleinschmidt-DeMasters BK, Lillehei KO, Damek DM, Harris JG. Gliomatosis cerebri: neurobehavioral and neuropathological observations. Cogn Behav Neurol 2003;16:149-159.
81. **Filley CM**, Halliday W, Kleinschmidt-DeMasters BK. [The effects of toluene on the central nervous system.](https://pubmed.ncbi.nlm.nih.gov/14748556/)J Neuropathol Exp Neurol 2004;63:1-12.
82. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, **Filley CM**. Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol 2005;36;282-290.
83. Hall DA, Leehey MA, **Filley CM**, Steinbart E, Montine T, Schellenberg GD, Bosque P, Nixon R, Bird T.  *PRNP* H187R mutation associated with neuropsychiatric disorders in childhood and dementia. Neurology 2005;64:1304-1306.
84. **Filley CM**. The behavioral neurology of white matter**:** diagnosis of major disorders and syndromes. Appl Neurology 2005;1:25-38.
85. Frey LC, Ringel SP, **Filley CM**. The natural history of cognitive dysfunction in late-onset GM2 gangliosidosis. Arch Neurol 2005;62:989-994.
86. **Filley CM**. Neurobehavioral aspects of cerebral white matter disorders. Psychiatr Clin North Am 2005;28:685-700.
87. Kozora E, Arciniegas DB, **Filley CM**, Ellison M, West S, Brown MS, Simon JS. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus. Preliminary data. Cogn Behav Neurol 2005:18:159-162.
88. Anderson CA, Arciniegas DB, **Filley CM**. Treatment of acute ischemic stroke: does it impact neuropsychiatric outcome? J Neuropsychiatry Clin Neurosci 2005;17:486-488
89. **Filley CM.** White matter and behavioral neurology. Ann NY Acad Sci 2005;1064:162-183.
90. Kleinschmidt-DeMasters BK, Rojiani AM, **Filley CM**. Central pontine myelinolysis: *then . and now*. J Neuropathol Exp Neurol 2006;65:1-11.
91. **Filley CM**, Ramsberger G, Menn L, Wu J, Reid BY, Reid AL. Primary progressive aphasia in a bilingual woman. Neurocase 2006;12:296-299.
92. Kleinschmidt-DeMasters BK, **Filley CM**, Rojiani AM. Overlapping features of extrapontine myelinolysis and acquired chronic (non-Wilsonian) hepatocerebral degeneration. Acta Neuropathol 2006;112:605-616.
93. Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, **Filley CM**. MS vs. HD: Can white matter and subcortical gray matter pathology be distinguished neuropsychologically? J Clin Exp Neuropsychol 2007;29:142-154.
94. Anderson CA, Bosque P, **Filley CM**, Arciniegas DB, Kleinschmidt-DeMasters BK, Pape J, Tyler KL. The Colorado Surveillance Program for Chronic Wasting Disease transmission to humans. Lessons from two highly suspicious, but negative cases. Arch Neurol 2007;64:439-441.
95. Phinney E, Pennington BF, Olson R, **Filley CM**, Filipek PA. Brain structure correlates of component reading processes: implications for reading disability. Cortex 2007;43:777-791.
96. Bernard TJ, Mull BR, Handler MH, Harned RK, **Filley CM**, Kumpe DA, Tseng BS. An 18-year-old man with fenestrated vertebral arteries, recurrent stroke and successful angiographic coiling. J Neurol Sci 2007;260:279-282.
97. **Filley CM,** Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Murrell JR, Boyer PJ, Kleinschmidt-DeMasters BK, Ghetti B. The genetics of very early onset Alzheimer’s Disease. Cogn Behav Neurol 2007;20:149-156.
98. Wortzel H, Binswanger IA, Martinez R, **Filley CM**, Anderson CA. Crisis in the treatment of incompetence to proceed to trial: harbinger of a systemic illness.J Am Acad Psychiatry Law 2007;35:357-363.
99. Oster TJ, Anderson CA, **Filley CM**, Wortzel H, Arciniegas DB. Quetiapine for mania due to traumatic brain injury. CNS Spectrums 2007;12:764-769
100. Rothman MS, Arciniegas DB, **Filley CM**, Wierman ME. The neuroendocrine effects of traumatic brain injury. J Neuropsychiatry Clin Neurosci 2007;19:363-372.
101. Hudson LA, Rollins YD, Anderson CA, Johnston-Brooks C, Tyler KL, **Filley CM**. Reduplicative paramnesia in Morvan’s syndrome. J Neurol Sci 2008;267:154-157.
102. Wortzel HS, **Filley CM**, Anderson CA, Oster T, Arciniegas DB. Forensic applications ofcerebral single photon emission computed tomography in mild traumatic brain injury. J Am Acad Psychiatry Law 2008;36:310-322.
103. Kozora E, Hanly JG, Lapteva L, **Filley CM**. Cognitive dysfunction in systemic lupus erythematosus. Past, present and future. Arthritis Rheum 2008;58:3286-3298.
104. Kozora E, Arciniegas DB, **Filley CM**, West S, Brown M, Miller D, Grimm A, Devore MD, Wingrove C, Zhang L. Cognitive and neurologic status in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. Arthritis Care Res 2008;59:1639-1646.
105. Schmahmann JD, Smith EE, Eichler FS, **Filley CM**. Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann NY Acad Sci 2008;1142:266-309.
106. **Filley CM**, Kozora E, Brown MS, Miller DE, West SG, Arciniegas DB, Grimm A, Zhang L. White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus. Cogn Behav Neurol 2009;22:38–44.
107. Homaifar BY, Brenner LA, Gutierrez PM, Harwood JF, Thompson C, **Filley CM**, Kelly JP, Adler LE. Sensitivity and specificity of the Beck Depression Inventory-II in persons with traumatic brain injury. Arch Phys Med Rehabil 2009;90:652-656.
108. Howard KL, **Filley CM**. Advances in genetic testing for Alzheimer’s Disease. Rev Neurol Dis 2009;6:26-32.
109. Brousseau KM, **Filley CM**, Kaye K, Kiser JJ, Adler LE, Connick E. Dementia with features of Alzheimer's Disease and HIV-Associated Dementia in an elderly man with AIDS 2009;23:1029-1031.
110. Brenner LA, Ladley-O'Brien SE, Harwood JEF, **Filley CM**, Kelly JP, Homaifar BY, Adler LE. An exploratory study of neuroimaging, neurologic, and neuropsychological findings in veterans with traumatic brain injury and/or posttraumatic stress disorder. Mil Med 2009;174:347-352.
111. Butler MA, Corboy JR, **Filley CM**. How the conflict between American Psychiatry and Neurology delayed the appreciation of cognitive dysfunction in multiple sclerosis. Neuropsychol Rev 2009;19:399-410.
112. Bahraini NH, Brenner LA, Harwood JEF, Homaifar BY, Ladley-O'Brien SE, **Filley CM**, Kelly JP, Adler LE. Utility of the Trauma Symptom Inventory for the assessment of post-traumatic symptoms in veterans with a history of psychological trauma and/or brain injury. Mil Med 2009;174:1005-1009.
113. **Filley CM.** Exploring white matter microstructure. New insights from diffusion tensor imaging. Neurology 2009;73:1718-1719.
114. Betjemann RS, Johnson EP, Barnard H, Boada R, **Filley CM**, Filipek PA, Willcutt EG, DeFries JC, Pennington BF. Genetic covariation between brain volumes and IQ, reading performance, and processing speed. Behav Genet 2010;40:135-145.
115. **Filley CM**. White matter: organization and functional relevance. Neuropsychol Rev 2010;20:158-173.
116. Kenfield MC, Arciniegas DB, Anderson CA, Howard KL, **Filley CM**. When cognitive evaluation does not disclose a neurologic disorder: experience of a university behavioral neurology clinic. Cogn Behav Neurol 2010;23:112-118.
117. Kozora E, West SG,Maier SF, **Filley CM**,Arciniegas DB, Brown M, Miller D, Grimm A, Zhang L.Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J Neurol Sci 2010;295:87-91.
118. **Filley CM**. White matter: beyond focal disconnection. Neurol Clin 2011; 9:81-97.
119. Hilger A, Kong APH, Menn L, Yan Y, Ramsberger G, **Filley C**. Longitudinal output changes in a case of logopenic bilingual PPA. Procedia Soc Behav Sci 2011;23:31-32
120. **Filley CM**, Anderson CA. Dementia: five new things. Neurology 2011;76 (Suppl 2):S26-S30.
121. Kozora E, **Filley CM**. Cognitive dysfunction and white matter abnormalities in systemic lupus erythematosus. J Int Neuropsychol Soc 2011;17:1-8.
122. Kozora E, Brown MS, **Filley CM,** Zhang L, Miller DE, West SG, Pelzman J, Arciniegas DB. Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus. Lupus 2011;20:598-606.
123. **Filley CM**, Brodtmann A. Lacunes and cognitive decline: little things matter. Neurology 2011;76:1856-1857.
124. Wortzel HS, Kraus MF, **Filley CM**, Anderson CA, Arciniegas DB. Diffusion tensor imaging in mild traumatic brain injury litigation. J Am Acad Psychiatry Law 2011;39:511-523.
125. Pelak VS, Smyth SA, Boyer PJ, **Filley CM**. Computerized visual field deficits in posterior cortical atrophy. Neurology 2011;39:2119-2122.
126. Hurley RA, **Filley CM**, Taber KJ. Central pontine myelinolysis: a metabolic disorder of myelin. J Neuropsychiatry Clin Neurosci 2011;23:369-374.
127. Kozora E, **Filley CM**, Zhang L, Brown MS, Miller DE, Arciniegas DB, Pelzman J, West SG. Immune function and brain abnormalities in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 2012;21:402-411.
128. **Filley CM**. White matter dementia. Ther Adv Neurol Disord 2012;5:267-277.
129. Kozora E, Erkan D, West SG, **Filley CM**, Zhang L, Ramon G, Duggan E, Lockshin MD Site differences in mild cognitive dysfunction (MCD) among patients with systemic lupus erythematosus (SLE). Lupus 2013;22:73-80.
130. **Filley CM.** Toluene abuse and white matter: a model of toxic leukoencephalopathy. Psychiatr Clin North Am 2013;36:293-302.
131. Kozora E, Arciniegas DB, Duggan E, West S, Brown M, Ellison M, **Filley CM.**White matter abnormalities and working memory impairment in systemic lupus erythematosus (SLE). Cogn Behav Neurol 2013;26:63-72.
132. Bigler ED, Deibert E, **Filley CM**. When is a concussion no longer a concussion? Neurology 2013;81:14-15.
133. Shipley SM, Frederick MC, **Filley CM**, Kluger BM. Potential for misdiagnosis in community-acquired PET scans for dementia. Neurol Clin Pract 2013;3:305-312.
134. Lafosse JM, Mitchell SM, Corboy JR, **Filley CM**. The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc 2013;19:995-1008.
135. Hall DA, Bennett D, **Filley CM,** Shah R, Kluger BM, Ouyang B, Berry-Kravis E. Fragile X gene expansions are not associated with dementia. Neurobiol Aging 2014;35:2637-2638.
136. **Filley CM,** Bernick C. Children and football: a cautionary tale. Neurology 2015:84:1068-1069.
137. **Filley CM**, Brown MS, Onderko K, Ray M, Bennett RE, Berry-Kravis E, Grigsby J. White matter disease and cognitive impairment in FMR1 premutation carriers. Neurology 2015;84:2146-2152.
138. **Filley CM**. Alzheimer’s disease prevention: new optimism. Neurol Clin Pract 2015:5:193-200.
139. Pelak VS, **Filley CM**. Clinical and imaging clues to posterior cortical atrophy. Neurol Clin Pract 2015;5:270-271.
140. **Filley CM**. Occupation and the risk of chronic toxic leukoencephalopathy. Handb Clin Neurol 2015;131:73-91.
141. Anderson CA, Woodcock JH, **Filley CM.** Transient prosopagnosia with right temporal astrocytoma. J Neuropsychiatry Clin Neurosci 2016;28:e13-e14.
142. **Filley CM**. Fragile X tremor ataxia syndrome and white matter dementia. Clin Neuropsychol 2016;30:901-912.
143. Anderson CA, **Filley CM**. Delusional misidentification syndromes: progress and new challenges. J Neuropsychiatry Clin Neurosci 2016;28:160-161.
144. Debrey SM, Leehey MA, Klepitskaya O, **Filley CM**, Shah RC, Kluger B, Berry-Kravis E, Spector E, Tassone F, Hall DA. Clinical phenotype of adult Fragile X gray zone allele carriers: a case series. Cerebellum 2016;15:623-631.
145. **Filley CM**. White matter dementia:  origin, development, progress, and prospects. J Neuropsychiatry Clin Neurosci 2016;28:262-272.
146. Kozora E. Uluğ AM, Erkan D, Vo A, **Filley CM**, Ramon G, Burleson A, Zimmerman R, Lockshin MD. Functional MRI of working memory and executive dysfunction in systemic lupus erythematosus and antiphospholipid antibody positive patients. Arthritis Care Res 2016;68:1665-1663.
147. **Filley CM**, Fields RD. White matter and cognition: making the connection. J Neurophysiol 2016;116:2093-2104.
148. **Filley CM**. Prematurity, white matter, and cognition: support for leukocentrism. Dev Med Child Neurol 2017;59:888.
149. **Filley CM**, McConnell BV, Anderson CA. The expanding prominence of toxic leukoencephalopathy.  J Neuropsychiatry Clin Neurosci 2017;29:308-318.
150. Kluger BM, Persenaire MJ, Holden SK, Palmer LT, Redwine H, Berk J, Anderson CA, **Filley CM**, Kutner J, Miyasaki J, Carter J. Implementation issues relevant to outpatient neurology palliative care. Ann Palliat Med 2017;3:339-344.
151. **Filley CM**, Burke H, Anderson CA. Anterior cerebral artery territory infarction-related resolution of chronic lower back pain, J Neuropsychiatry Clin Neurosci 2018;30:81-83.
152. **Filley CM**, Kelly JP. White matter and cognition in traumatic brain injury. J Alzheimers Dis 2018;65:345-362.
153. Kozora E, **Filley CM**, Erkan D, Uluğ AM, Vo A, Ramon G, Burleson A, Zimmerman RD, Lockshin MD.  Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus. Lupus 2018;27:1810-1818.
154. **Filley CM**, Arciniegas DB, Brenner LA, Anderson CA, Kelly JP.  Chronic traumatic encephalopathy: a clinical perspective.  J Neuropsychiatry Clin Neurosci 2019;31:170-172.
155. **Filley CM**. History of subcortical cognitive impairment. In: Bogousslavsky J, Boller F, Iwata M, eds. A History of Neuropsychology. Front Neurol Neurosci 2019;44:108-117.
156. Bateman JR, **Filley CM**, Ross ED, Bettcher BM, Hubbard IH, Babiak M, Pressman PS. Aprosodia and prosoplegia with right frontal neurodegeneration. Neurocase 2019;25:187-194.
157. Bateman JR, **Filley CM**, Kaplan RI, Heffernan KS, Bettcher BM. Lifetime surgical exposure, episodic memory, and forniceal microstructure in older people. J Clin Exp Neuropsychol 2019;41:1048-1059.
158. **Filley CM**. Social cognition and white matter: connectivity and cooperation. Cogn Behav Neurol 2020;33;67-75.
159. **Filley CM**. On the trail of white matter. J Neuropsychiatry Clin Neurosci 2020;32:312-313.
160. **Filley CM.** Progress in the diagnosis of traumatic brain injury. Neurology 2020;95:235-236.
161. **Filley CM,** Kletenik I, Churchland PS. Morality and the brain: the right hemisphere and doing right. Cogn Behav Neurol 2020;33:304-307.
162. Elliott G, **Filley CM**, McCann AV, Diefenbach HA, Lucie A, Heibel ME, Vanderryn J. Art informing interdisciplinary care for a veteran recovering from traumatic brain injury: a case study. J Human Rehab, published online 30 April 2021 at jhrehab.org.
163. **Filley CM.** Cognition in cerebral palsy: white matter matters. Eur J Paediatr Neurol 2021;32:A1.
164. **Filley CM**. White matter and human behavior. Science 2021;372;1265-1266.
165. **Filley CM.** White matter disease and psychiatric dysfunction: clinical and neurobiological insights. J Neuropsychiatry Clin Neurosci 2021; 33:178-179.
166. Rajic AJ, Pressman PS, Woodcock JH, Chial HJ, **Filley CM.** Use of coffee grounds to test olfaction for predicting cognitive dysfunction and decline. J Neurol Sci 2021; 427:117516.
167. **Filley CM.** Cognitive dysfunction in white matter disorders: new perspectives in treatment and recovery. J Neuropsychiatry Clin Neurosci 2021;33:349-355.
168. Johnston-Brooks CH, Grassmeyer RP, **Filley CM**, Kelly JP. The Marcus Institute for Brain Health: an integrated practice unit for the care of traumatic brain injury in military veterans. Brain Inj 2021;35:1702-1710.
169. **Filley CM.** White matter, behavioral neurology, and the influence of corticocentrism. Cogn Behav Neurol 2022;35:147-152.
170. Macchi ZA, Carlisle TC, **Filley CM**. Prognosis in substance abuse-related acute toxic leukoencephalopathy: a scoping review. J Neurol Sci 2022;442:120420.
171. Hebert JR, **Filley CM**. Multisensory integration and white matter pathology: contributions to cognitive dysfunction. Front Neurol 2022 Nov 2;13:1051538.
172. **Filley CM**. White matter dementia then . . . and now. Front Neurol 2022 Nov 21;13:1043583.
173. Carlisle TC, Birlea M, Restrepo D, **Filley CM**. Headache-associated phantosmia as a harbinger of Lewy body dementia. J Neuropsychiatry Clin Neurosci 2023;35:92-97.
174. Kelly JP, Priemer DS, Perl DP, **Filley CM**. Sports concussion and chronic traumatic encephalopathy: finding a path forward. Ann Neurol 2023;93:222-225.
175. Holden SK, Bettcher BM, **Filley CM**, Lopez-Paniagua D, Pelak VS. [Posterior white matter integrity and self-reported posterior cortical symptoms using the Colorado Posterior Cortical Questionnaire.](https://pubmed.ncbi.nlm.nih.gov/36816576/) Front Neurol 2023 Feb 1;14:1072938.
176. Pressman PS, Chen KH, Casey J, Sillau S, Chial H, **Filley CM**, Miller BL, Levenson RW. Incongruences between facial expression and self-reported emotional reactivity in frontotemporal dementia and related disorders. J Neuropsychiatry Clin Neurosci 2023; 35:192-201.
177. Thaker AA, McConnell BV, Rogers DM, Carlson NE, Coughlan C, Jensen AM, Lopez-Paniagua D, Holden SK, Pressman PS, Pelak VS, **Filley CM**, Potter H, Solano DA, Heffernan KS, Bettcher BM. Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women. Brain Behav Immun 2023: 113: 124-135.
178. **Filley CM**, Penner I-K, Schäfer L, Köhler W. Editorial. White matter dementia: neuropathological and neuropsychological underpinnings and state of the art diagnosis methods and treatments. Front Neurol 2023 Aug 17;14:1268295.
179. Utter B, Anderson CA, **Filley CM**, Kelly JP, Johnston-Brooks C, Arciniegas DB.Cannabis use in a cohort of healthcare-seeking United States military veterans with persisting symptoms after mild traumatic brain injury: preliminary observations. Mil Med 2023;188:e2158.
180. Pressman PS, Molden J, Wortzel HS, Stoddard J, Plys E, Woodcock JH, **Filley CM**, Arciniegas DB. Psychiatric screening measures in behavioral variant frontotemporal dementia. J Neuropsychiatry Clin Neurosci, in press.
181. Sanders JS, Mabry M, Scarbro S, **Filley CM**. The new frontier: the first year of an adult neurodevelopmental disabilities clinic. Cogn Behav Neurol, in press.

**Books**

1. **Filley CM**. Neurobehavioral Anatomy. Niwot, CO: University Press of Colorado, 1995.
2. **Filley CM**.Neurobehavioral Anatomy, 2nd edition. Boulder, CO: University Press of Colorado, 2001.
3. **Filley CM**. The Behavioral Neurology of White Matter. New York: Oxford University Press, 2001.
4. **Filley CM**. Neurobehavioral Anatomy, 3rd edition. Boulder, CO: University Press of Colorado, 2011.
5. **Filley CM.** The Behavioral Neurology of White Matter. 2nd edition. New York: Oxford University Press, 2012.
6. Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology & Neuropsychiatry. Cambridge: Cambridge University Press, 2013.
7. **Filley CM**. White Matter Dementia. Cambridge: Cambridge University Press, 2016.

**Book Chapters**

1. **Filley CM**, Heaton RK, Franklin GM, Thompson LL, Nelson LM. Effects of disease course on neuropsychological functioning. In: Rao SM, ed. Neurobehavioral Aspects of Multiple Sclerosis. New York: Oxford University Press, 1990.
2. Franklin GM, Nelson LM, Heaton RK, **Filley CM**. Dementia in multiple sclerosis: a clinical perspective. In: Rao SM, ed. Neurobehavioral Aspects of Multiple Sclerosis. New York: Oxford University Press, 1990.
3. Heaton RK, Thompson LL, Nelson LM, **Filley CM**, Franklin GM. Brief and intermediate length screening of neuropsychological impairment. In: Rao SM, ed. Neurobehavioral Aspects of Multiple Sclerosis. New York: Oxford University Press, 1990.
4. **Filley CM**, Kelly JP. Neurobehavioral effects of focal subcortical lesions. In: Cummings JL, ed. Subcortical Dementia. New York: Oxford University Press, 1990.
5. **Filley CM**. Alzheimer's Disease and other dementia states. In: Schrier RW, ed. Geriatric Medicine. Philadelphia: W. B. Saunders, 1990.
6. Kelly JP, **Filley CM**. Neurobehavioral toxicology. In: Sullivan JB, Krieger GR, eds. Hazardous Materials Toxicology. Baltimore: Williams and Wilkins, 1992.
7. Kelly JP, **Filley CM**. Traumatic brain injury in children. In: Simkins CM, ed. Analysis, Understanding and Presentation of Cases Involving Traumatic Brain Injury. Washington D.C.: National Head Injury Foundation, 1994.
8. **Filley CM**. Neurobehavioral disorders in workers. In: Rosenberg NL, ed. Occupational and Environmental Neurology. Stoneham, Massachusetts: Butterworth-Heinemann, 1995.
9. Anderson CA, **Filley CM**. Behavioral presentations of medical and neurologic disorders. In: Jacobson JL, Jacobson AM, eds. Psychiatric Secrets. 1st ed. Philadelphia: Hanley and Belfus, 1996.
10. **Filley CM**. Neurobehavioral aspects of cerebral white matter disorders. In: Fogel BS, Schiffer RB, Rao SM, eds. Neuropsychiatry. Baltimore: Williams and Wilkins, 1996.
11. Meredith LA, **Filley CM**. Acute confusional state. In: Schrier RW, Jahnigen DW, eds. Geriatric Medicine. Cambridge, Massachusetts: Blackwell, 1996.
12. Filipek PA, Pennington BF, Simon JS, **Filley CM**, DeFries JC. Structural and functional neuroanatomy in reading disorder. In: Duane DD, ed. Reading and Attention Disorder: Neurobiological Correlates. Parkton, Maryland: York Press, 1999.
13. **Filley CM**. White-matter disorders. In: Fogel BS, Schiffer RB, Rao SM, eds. Synopsis of Neuropsychiatry. Philadelphia: Lippincott Williams and Wilkins, 2000.
14. Anderson CA, **Filley CM**. Behavioral presentations of medical and neurologic disorders. In: Jacobson JL, Jacobson AM, eds. Psychiatric Secrets, 2nd ed. Philadelphia: Hanley and Belfus, 2001.
15. **Filley CM**, Kelly JP. Clinical neurotoxicology and neurobehavioral toxicology. In: Sullivan JB, Krieger GR, eds. Clinical Environmental Health and Toxic Exposures. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
16. **Filley CM**. Cerebral white matter disorders. In: Ramachandran VS, ed. Encyclopedia of the Human Brain. San Diego: Academic Press, 2002.
17. **Filley CM**. Neuroanatomy. In: Ramachandran VS, ed. Encyclopedia of the Human Brain. San Diego: Academic Press, 2002.
18. **Filley CM**. Norman Geschwind. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
19. **Filley CM**. Alexander Romanovich Luria. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
20. **Filley CM**. Korbinian Brodmann. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
21. **Filley CM**. Alois Alzheimer. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
22. **Filley CM**. Pierre Paul Broca. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
23. **Filley CM**. Joseph Francois Felix Babinski. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
24. **Filley CM**. Paul Ferdinand Schilder. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
25. **Filley CM**. Walter Edward Dandy. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 1st ed. San Diego: Academic Press, 2003.
26. **Filley CM**. White matter disorders. In: Schiffer RB, Rao SM, Fogel BS, eds. Neuropsychiatry, 2nd ed. Baltimore: Lippincott Williams and Wilkins, 2003.
27. **Filley CM**. Encephalopathies. In: Rizzo M, Eslinger PJ, eds. Principles and Practice of Behavioral Neurology and Neuropsychology. Philadelphia: W. B. Saunders, 2004.
28. **Filley CM**. Dementia. In: Holmes GL, Cohen JA, Levin M, eds. Educational Review Manual in Neurology. New York: Castle Connolly Graduate Medical Publishing, Ltd., 2006.
29. **Filley CM**. Neuroanatomy for the neuropsychologist. In: Morgan JE, Ricker JH, eds. Textbook of Clinical Neuropsychology. New York: Taylor and Francis, 2008.
30. **Filley CM**. Dementia. In: Levin M, Holmes GL, Cohen JA, eds. Educational Review Manual in Neurology. 2nd ed. New York: Castle Connolly Graduate Medical Publishing, Ltd., 2008.
31. **Filley CM**. The frontal lobes. In: Boller F, Finger S, Tyler KL, eds. Handbook of Clinical Neurology. Edinburgh: Elsevier 2009; 95: 557-570.
32. **Filley CM**. Neurobiology of white matter disorders. In: Jones DK, ed. Diffusion MRI. Theory, Methods, and Applications New York: Oxford University Press, 2011.
33. **Filley CM**, Anderson CA, Arciniegas DB Introduction. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013.
34. Anderson CA, Arciniegas DB, Hall DA, **Filley CM**. Behavioral neuroanatomy. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013
35. **Filley CM**. White matter. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013.
36. Anderson CA, **Filley CM**, Arciniegas DB, Kelly JP. Arousal. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013
37. Kleinschmidt-DeMasters BK, Howard KD, Ojemann S, **Filley CM**. Neuropathological assessment. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013
38. **Filley CM**. Neurotoxicology. In: Arciniegas DB, Anderson CA, **Filley CM**. Behavioral Neurology and Neuropsychiatry. Cambridge: Cambridge University Press, 2013.
39. **Filley CM**. Norman Geschwind. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd ed. San Diego: Academic Press, 2014.
40. **Filley CM**. Alois Alzheimer. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd ed. San Diego: Academic Press, 2014.
41. **Filley CM**. Alexander Romanovich Luria. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd ed. San Diego: Academic Press, 2014.
42. **Filley CM**. Korbinian Brodmann. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd ed. San Diego: Academic Press, 2014.
43. **Filley CM**. Walter Edward Dandy. In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd ed. San Diego: Academic Press, 2014.
44. Julian LJ, **Filley CM**. Rheumatologic and other autoimmune dementias. In: Geschwind MD, Belkoura CR, eds. Non-Alzheimer’s and atypical dementia. Chichester, UK: Wiley-Blackwell, 2016.
45. **Filley CM**. The history of behavioral neurology. In: Barr W, Bielauskas LA. The Oxford Handbook of History of Clinical Neuropsychology.  Oxford: Oxford University Press, 2016.
46. **Filley CM**. White matter diseases of the frontal lobes. In: Miller BL, Cummings JL, eds. The Human Frontal Lobes. New York: Guilford Press, 2017.
47. **Filley CM**, Bigler ED. Neuroanatomy for the neuropsychologist. In: Morgan JE, Ricker JH, eds. Textbook of Clinical Neuropsychology. 2nd ed. New York: Routledge, 2018.
48. Kozora E, Burleson A, **Filley CM**. Neuropsychological functioning in autoimmune disorders. In: Morgan JE, Ricker JH, eds. Textbook of Clinical Neuropsychology. 2nd ed. New York: Routledge, 2018.
49. Anderson CA, Arciniegas DB, **Filley CM**. The neuropsychiatry of hypoxic-ischemic brain injury. In: Arciniegas DB, Yudofsky SC, Hales RE, eds. Neuropsychiatry and Behavioral Neurosciences, 6th ed. Arlington, VA: American Psychiatric Publishing, Inc., 2018.
50. Brenner LA, Otis J, Grassmeyer RP, Adams RS, Laker SR, **Filley CM**. Assessment and management of psychiatric symptoms among adults with mild traumatic brain injury.  In: Eapen BC, Cifu DX, eds. Concussion: Assessment, Management, and Rehabilitation. New York: Elsevier, 2020.
51. **Filley CM**, Kelly JP. White matter and cognition in traumatic brain injury. In: Castellani RJ, ed. Handbook of Traumatic Brain Injury and Neurodegeneration. Amsterdam: IOS Press, 2020.
52. **Filley CM.** White matter dementia**.** In: England JD, eds. Encyclopedia of the Neurological Sciences, 3rd ed. Cambridge, MA: Elsevier, in press.

### Other Journal Articles and Publications

1. Kelly JP, **Filley CM**. Neurological aspects of taste and smell. Oto 88, 1988; 2: 7-9.
2. **Filley CM**. What does a neurologist want from a neuropsychologist? Colorado Psychological Association Bulletin, July 1988: 3-4.
3. **Filley CM**. When dementia means Creutzfeldt-Jakob Disease. Geriatric Consultant, September/October 1991; 14-15.
4. **Filley CM**. Beating the heat. Courtlandt Forum 1993; 6: 50.
5. **Filley CM**. Confronting Alzheimer's Disease: the physician's perspective. Alzheimer's Association Rocky Mountain Chapter Newsletter 1996; 16(4): 4-5.
6. **Filley CM**. International neurology. J Int Neuropsychol Soc 1997; 3: 300-301. (Review of Mohr JP, Gautier JC. *Guide to Clinical Neurology*).
7. **Filley CM**. Summary and case overview: white matter dementia in CADASIL. Review Series Dementia 2000; 3: 12-13.
8. **Filley CM**, Kelly JP, Price BH. Violence and the brain: an urgent need for research. The Scientist, April 2, 2001.
9. Hewitt B, **Filley CM**. Clinical trials – what are they all about? Senior Focus Heather Gardens Edition, Denver, CO, June 2002: 8.
10. **Filley CM**. What’s In A Name? J Int Neuropsychol Soc 2002; 8: 868. (Review of Koehler PJ, Bruyn GW, Pearce JMS, eds. *Neurological Eponyms*).
11. **Filley CM**. International thriller: “Eye Spy” meets neurology? Neurology Today 2003; 3(7): 17. (Review of Rosenfield DB. *Dick Swept, M.D.: Tomorrow the World*).
12. **Filley CM**. A neurologist examines literary creativity. Neurology Today 2004; 4(3): 32-41. (Review of Flaherty AW. *The Midnight Disease: The Drive to Write, Writer’s Block, and the Creative Mind*).
13. **Filley CM.** Ramachandran offers new light on consciousness. Neurology Today 2004; 4 (11); 78-79. (Review of Ramachandran VS. *A Brief Tour of Human Consciousness: From Impostor Poodles to Purple Number*s).
14. **Filley CM.** The behavioral neurology of white matter: diagnosis of major disorders and syndromes. Psychiatric Times, April 9, 2005.
15. **Filley CM**. Why the white brain matters. Cerebrum 2005; 7: 53-66.
16. **Filley CM**. Leukoencephalopathy, disconnection, and cognitive neuroscience. US Neurological Disease 2006; 64-65.
17. **Filley CM.** Dementia through the eyes of a poet. Neurology Today 2006; 6(18): 12-13. (Review of Skloot F. *A World of Light*).
18. **Filley CM.** Tracking white matter. Lancet Neurology 2007; 6: 27. (Review of Schmahmann JD, Pandya DN. *Fiber Pathways of the Brain*).
19. **Filley CM.** Diseases of Cerebral White Matter. Syllabus for half-day course on Structure Function Correlations in Behavioral Neurology, 59th Annual Meeting of the American Academy of Neurology, Boston, Massachusetts.
20. **Filley CM**. Embracing the peculiarities of Asperger’s Syndrome. Neurology Today 2007; 7(9): 28 (Review of Tammet D. *Born on a Blue Day: Inside the Extraordinary Mind of an Autistic Savant*).
21. **Filley CM**. A love story in the grip of Alzheimer’s Disease. Neurology Today 2007; 7(12): 20-22 (Review of *Away From Her*, a film by Sarah Polley).
22. **Filley CM.** Diseases of Cerebral White Matter. Syllabus for half-day course on Structure Function Correlations in Behavioral Neurology. American Academy of Neurology 60th Annual Meeting, Chicago, Illinois.
23. **Filley CM**. Caregivers take center stage in “The Savages.” Neurology Today 2008; 8(3): 20. (Review of *The Savages*, a film by Tamara Jenkins).
24. **Filley CM**. A compelling synthesis of literature and science makes for a poignant exploration of familial Alzheimer Disease. Neurology Today 2008; 8(15): 24 (Review of Block SM. *The Story of Forgetting*).
25. **Filley CM**. The singularity of being human – and the paragon of animals. Neurology Today 2008; 8(21): 10. (Review of Gazzaniga MS. *Human.* *The Science Behind What Makes Us Unique*).
26. **Filley CM**. What it is like to have Alzheimer Disease: dementia from the inside out**.** Neurology Today 2009; 9(11): 24. (Review of Harvey S. *The Wilderness*).
27. **Filley CM.** A critical reconsideration of Alzheimer Disease. Neurology Today 2010; 10(4): 15-16. (Review of Ballenger JF, Lyketsos CG, Whitehouse PJ, Rabins PV, and Karlawish JHT. *Treating Dementia: Do We Have a Pill For It?*).
28. **Filley CM**. White Matter Dementia. Syllabus for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 62nd Annual Meeting, Toronto, Ontario.
29. **Filley CM**. Two personal explorations of visual dysfunction. Neurology Today 2011; 11(2): 24-25. (Review of Sacks O. *The Mind’s Eye* and Sellers H. *You Don’t Look Like Anyone I Know*).
30. **Filley CM**. White Matter Dementia. Syllabus for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 63rd Annual Meeting, Honolulu, Hawaii.
31. **Filley CM**. White Matter Dementia. Syllabus for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 64th Annual Meeting, New Orleans, Louisiana.
32. **Filley CM.** Bridging the gap between science and art. Neurology Today 2012, 12 (11): 38-39. (Review of Kandel ER. *The Age of Insight: The Quest to Understand the Unconscious in Art, Mind, and Brain, From Vienna 1900 to the Present*).
33. **Filley CM**. On seeing and hearing things that are not there. Neurology Today 2012; 12 (24): 26-27. (Review of Sacks O. *Hallucinations*).
34. **Filley CM**. White Matter and Dementia. Syllabus for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 65th Annual Meeting, San Diego, California
35. **Filley CM.** A lively tale of proteins gone awry. Neurology Today 2013; 13(10): 16. (Review of Ingram J. *Fatal Flaws: How a Misfolded Protein Baffled Scientists and Changed the Way We Look at the Brain*).
36. **Filley CM.** Intelligence training: promise or hype? Neurology Today 2014; 14(4): 12. (Review of Hurley D. *Smarter: The New Science of Building Brain Power*).
37. **Filley CM**. White Matter and Dementia. Syllabus for half-day course on Non-Alzheimer’s Dementia. American Academy of Neurology 66th Annual Meeting, Philadelphia, Pennsylvania.
38. **Filley CM**.  Proteins, prions, and paradigm shift – persistence and a little self-promotion help. Neurology Today 2014; 14(9): 38-40. (Review of Prusiner SB. *Madness and Memory: A New Biological Principle of Disease*).
39. **Filley CM.** Oliver Sacks: reflections on a life well-lived. Neurology Today 2015; 15(12): 15. 2015; 15(18): 15-16 2015; 15(18): 15-16 and 2015; 15(18): 15-16 (Review of Sacks O. *On the Move: A Life*).
40. **Filley CM.** In the tradition of Oliver Sacks, “The Brain with David Eagleman” brings the wonders of neuroscience to a wide audience. Neurology Today 2015; 15(24): 7 (Review of Eagleman D. *The Brain with David Eagleman*).
41. **Filley CM**. Across the great two-cultures divide. Neurology Today 2016; 16(20): 14-15. (review of Kandel ED. *Reductionism in Art and Brain Science: Bridging the Two Cultures*).
42. **Filley CM**. Postscript for Bawmann B. *Beagle On Board*. Pittsburgh: Dorrance Publishing Co., 2018.
43. **Filley CM.** What are white matter lesions, and when are they a problem?Brain & Life February/March 2022; 15.
44. **Filley C**. You’ve likely heard of the brain’s gray matter – here’s why the white matter is important too. The Conversation, May 5, 2022. <https://theconversation.com/youve-likely-heard-of-the-brains-gray-matter-heres-why-the-white-matter-is-important-too-180945>.

**Other Scholarship (Teaching Videotapes)**

1. **Filley CM**. “Alzheimer’s Disease Patient Demonstration.” University of Colorado School of Medicine, 1985.
2. **Filley CM**. “Dementia Patient Demonstration.” University of Colorado School of Medicine, 1985.
3. **Filley CM**. “Alzheimer’s Disease.” Employee Grand Rounds, Glaser Auditorium, University of Colorado Health Sciences Center, 1987.
4. **Filley CM**. "A Case of Bifrontal Meningioma with Abulia." University of Colorado School of Medicine, 1989.
5. **Filley CM**. "Living with Alzheimer's Disease: The Patient, The Family, The Role of the physician." University of Colorado School of Medicine, 1993.

**Letters to the Editor**

1. **Filley CM**. Serpents two will not do. N Engl J Med 1979; 300: 929.
2. Rosenberg NL, **Filley CM**, Hormes JT. Toluene abuse and neurologic impairment (reply). Neurology 1987; 37: 356.
3. **Filley CM**, Heaton RK. Neuropsychological features of early- and late-onset Alzheimer's Disease (reply). Arch Neurol 1987; 44: 797-798.
4. Schneck SA, Burkhardt CR, **Filley CM**, Kleinschmidt-DeMasters BK. Lewy body disease (reply). Neurology 1989; 39: 878-879.
5. **Filley CM**, Rosenberg NL. Toluene dementia (reply). Neurology 1990; 40: 1321.
6. **Filley CM**, Mitchell WD, Thompson TL, Culig KM, Byyny RL, LoVerde M. Lack of efficacy of Hydergine in Alzheimer's Disease (reply). N Engl J Med 1991; 324: 197-198.
7. Mitchell WD, **Filley CM**, Thompson TL. Hydergine in Alzheimer's Disease (reply). J Geriatr Psychiatr Neurol 1991; 4: 122-123.
8. **Filley CM**, Chapman MM, Dubovsky SL. Anticoagulant therapy for Alzheimer's Disease (reply). J Neuropsychiatry Clin Neurosci 1996; 8: 361-362.
9. Kelly JP, **Filley CM**. Proneness to psychological distress is associated with the risk of Alzheimer’s Disease. Neurology 2004; 63: 941.
10. **Filley CM**. Cognitively impaired, but voting: where’s the right balance? Cerebrum 2004; 6: 5-6.

**Abstracts**

1. **Filley CM**, Graff-Radford NR, Lacy JR, Heitner M, Earnest MP. Central and peripheral neurotoxicity of podophyllin resin. Neurology 1981;31(Suppl 2):149.
2. Cranberg LD, **Filley CM**, Hart EJ, Alexander MP. Acquired aphasia in childhood: clinical and CT investigations. Neurology 1984;34(Suppl 1):275.
3. **Filley CM**, Kelly MA, Hwang PALS, Earnest MP. An analysis of typical and "indeterminate" PLEDs. EEG Clin Neurophysiol 1984;58:32P.
4. **Filley CM**, Cranberg LD, Hart EJ, Alexander MP. Closed head injury in childhood: neurobehavioral outcome. Ann Neurol 1985;18:146-147.
5. Franklin GM, Heaton RK, **Filley CM**, Seibert CE, Nelson LM, Walford DR. Correlation of neuropsychological and magnetic resonance imaging (MRI) findings in chronic/progressive MS Neurology 1986;36(Suppl 1):185.
6. Rosenberg NL, Kleinschmidt-DeMasters BK, **Filley CM**, Dreisbach JN. Diffuse CNS demyelination due to chronic toluene inhalation: MRI and neuropathologic studies. Neurology 1986;36(Suppl 1):286.
7. **Filley CM**, Davis KA, Schmitz SP, Stears JC, Heaton RK, Kelly J, Culig KM, Eaves-Herrera MR. MRI findings in normal aging and Alzheimer's Disease. Neurology 1987;37(Suppl 1):157-158.
8. Burkhardt CR, **Filley CM**, Kleinschmidt-DeMasters BK, de la Monte S, Norenberg MD, Schneck SA. Diffuse Lewy Body Disease and progressive dementia. Neurology 1987;37(Suppl 1):331.
9. Rosenberg NL, Spitz MC, **Filley CM**, Schaumburg HH. Central nervous system effects of chronic toluene inhalation: clinical, brainstem evoked response, and MRI studies. Neurology 1988;38(Suppl 1):113.
10. Franklin GM, Nelson LM, **Filley CM**, Heaton RK. Prominent dementia in MS with minimal neurologic disability. Neurology 1988;38(Suppl 1):381.
11. **Filley CM**, Heaton RK, Rosenberg NL. Neuropsychological impairment in chronic toluene abuse. Neurology 1989;39(Suppl 1):177.
12. Heaton R, Montague J, **Filley C**, Avitable N. A test of Rourke's nonverbal learning disabilities model in dementia. J Clin Exp Neuropsychol 1990;12:29.
13. Kelly JP, Nichols J, Lillehei KO, **Filley CM**. Catastrophic outcome after repeated minor head injury in sports. Neurology 1990;40(Suppl 1):252.
14. Parker, WD, **Filley CM**, Parks JK. Reduced cytochrome oxidase activity in Alzheimer's Disease. Neurology 1990;40(Suppl 1):405.
15. Burkhardt C, Kelly JP, Lim YH, **Filley CM**, Parker WD. MPTP-like toxicity of neuroleptic medications. Ann Neurol 1991;30:296.
16. Jafek BW, **Filley CM**, Eller PM, Chapman MM, Johnson EW, Moran DT. Abnormal olfactory epithelium in biopsies of Alzheimer's patients. Chem Senses 1991;16:538-539.
17. Johnson EW, Jafek BW, Eller PM, **Filley CM**, Chapman MM, Kinnamon JC. Abnormalities in olfactory biopsies of Alzheimer's patients. Soc Neurosci Abstracts 1991;17:351.
18. Cullum CM, **Filley CM**, Kelly JP, Schneck SA. Utility of cognitive screening tests in patients with mild Alzheimer's disease. J Clin Exp Neuropsychol 1992;14:22-23.
19. **Filley CM**, Kleinschmidt-DeMasters BK, Gross KF. Neurobehavioral and pathologic features of frontotemporal degeneration. Neurology 1992;42(Suppl 3):411.
20. Eller PM, Jafek BW, Johnson EW, Bennett MC, **Filley CM**. A preliminary study of ultrastructural changes in the olfactory epithelium of a rat model for Alzheimer's disease. Chem Senses 1992;17:617.
21. Hughes D, **Filley CM**, Cullum CM. Brief recall tasks in the assessment of memory function in Alzheimer's disease. J Clin Exp Neuropsychol 1993;15:64.
22. Hughes D, **Filley CM**, Sherman SE, Cullum CM. Evaluation of premorbid intelligence indices in Alzheimer's Disease. Arch Clin Neuropsychol 1994;9:141-142.
23. Cullum CM, **Filley CM**, Kozora E. Episodic memory functions in advanced aging and early Alzheimer's Disease. J Int Neuropsychol Soc 1995;1:131.
24. Hughes D, **Filley CM**, Cullum CM. Executive, and memory functions in delusional and non-delusional patients with Alzheimer's Disease. J Int Neuropsychol Soc 1995;1:387.
25. Reardon MR, Wilkening GN, **Filley CM**. Neuropsychological effects of damage to prefrontal cortex during childhood. J Investig Med 1995;43(Suppl 1):94A.
26. **Filley CM**, Cullum CM. Education and cognitive function in Alzheimer's Disease. Neurology 1995;45 (Suppl 4):A356.
27. Filipek PA, Pennington BF, Holmes JL, Lefly D, Kennedy DN, Meyer JW, Lang JE, Gayan J, Galaburda AM, Simon JM, **Filley CM**, Caviness VS, DeFries JC. Developmental dyslexia: cortical and subcortical anomalies by magnetic resonance imaging-based morphometry. Ann Neurol 1995;38:509.
28. **Filley CM**. Alzheimer's Disease: It's irreversible but not untreatable. Parkinson/Alzheimer Digest, March 1996.
29. Wilkening GN, Reardon M, **Filley CM**, Shipman MS. Wisconsin Card Sort Performance in children with acquired frontal lobe lesions. Arch Clin Neuropsychol 1996;11:463-464.
30. Kozora E, Julian L, **Filley C**, Cullum CM. Cognitive functioning in patients with chronic obstructive pulmonary disease compared to mild Alzheimer Disease and normal control subjects. Arch Clin Neuropsychol 1996;11:412.
31. Miyake A, Ramsberger G, Menn L, Reilly K, **Filley C**. A selective preservation of numbers and geographic information in a severe anomic patient: a consequence of degraded visual knowledge base? Brain Lang 1996;55:34-37.
32. Anderson CA, Wilkening GN, **Filley CM**, Reardon M, Winston KR, Kleinschmidt-DeMasters BK. Neurobehavioral outcome in pediatric craniopharyngioma. Cancer and the Nervous System: 40th Annual Clinical Conference. The University of Texas MD Anderson Cancer Center, Houston, Texas, March 1997.
33. Anderson CA, Camp J, **Filley CM** Erotomania after aneurysmal subarachnoid hemorrhage: neuropsychiatric aspects. J Neuropsychiatry Clin Neurosci 1997;9:642.
34. Yee AS, Spitz MC, Shantz DL, Kelly JP, **Filley CM**. Postictal mania. Epilepsia 1998;39 (Suppl 6):241.
35. Meis JL, Noll EL, Hewitt BM, Dubovsky SL, **Filley CM**. Visuospatial dysfunction in Alzheimer's Disease. J Investig Med 1999;47:80A.
36. **Filley CM**, Thompson LL, Sze C-I, Simon JA, Paskavitz JF, Kleinschmidt-DeMasters BK. CADASIL: Neurobehavioral features in a confirmed case. J Neuropsychiatry Clin Neurosci 1999;11:139.
37. Sze C-I, Bi H, DeMasters BK, **Filley CM**, Martin LJ. Selective loss of synaptic vesicle proteins in Alzheimer's Disease. FASEB J 1999;13(4):A145.
38. Bi H, Sze C-I, Kleinschmidt-DeMasters BK, **Filley CM**, Martin LJ. Synaptobrevin may be an early marker for Alzheimer's Disease. J Neuropathol Exp Neurol 1999;58:532.
39. Sze C-I, Bi H, Kleinschmidt-DeMasters BK, **Filley CM**, Martin LJ. Selective regional alteration of N-methyl-D-aspartate (NMDA) receptor proteins NR2A and NR2B in Alzheimer's Disease (AD) and correlation with memory impairment. J Neuropathol Exp Neurol 1999;58:558.
40. Harris JG, **Filley CM**. CADASIL: Familial neuropsychological deficits in a rare genetic vascular disorder. Arch Clin Neuropsychol 1999;8:806-807.
41. Arciniegas DB, Olincy A, Topkoff J, McRae K, Cawthra E, **Filley CM**, Reite M, Adler LE. Impaired auditory gating and P50 nonsuppression following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2000;12:158.
42. Lafosse JM, Corboy JR, Leehey MA, McCulley F, Bouhall D, Carey CL, England DB, **Filley CM**. Neuropsychological distinction between subcortical white and gray matter dementia. J Int Neuropsychol Soc 2001;7:195.
43. England DB, Lafosse JM, Corboy JR, **Filley CM**, Bouhall D, McCulley E, Carey CL. The impact of neuropsychological and psychiatric symptoms in MS on caregiving spouses. J Int Neuropsychol Soc 2001;7:195-196.
44. Arciniegas DB, Topkoff JL, Anderson CA, **Filley CM**, Adler LE. Normalization of P50 physiology by donepezil hydrochloride in traumatic brain injury patients. J Neuropsychiatry Clin Neurosci 2001;13:140.
45. **Filley CM**, Kleinschmidt-DeMasters BK, Novins DK, Manson SM. Toxic leukoencephalopathy. October 14, 2001. [www.cu.edu/ColemanInstitute](http://www.cu.edu/ColemanInstitute).
46. **Filley CM**, Arciniegas DB, Wood GV, Anderson CA, Cheney E, Dygert CR, Summerall L, Goos RB. Geriatric treatment center: a contemporary model for collaboration between psychiatry and neurology. J Neuropsychiatry Clin Neurosci 2002;14:104.
47. Arciniegas DB, Topkoff JL, Anderson CA, **Filley CM**, Adler LE. Low-dose donepezil normalizes P50 physiology in traumatic brain injury patients. J Neuropsychiatry Clin Neurosci 2002;14:115.
48. Frey LC, Ringel SP, **Filley CM**. Cognitive dysfunction in adult GM2 gangliosidosis. Neurology 2002;53 (Suppl 3):A353.
49. Lafosse JM, Corboy JR, Leehey MA, Seeberger L, **Filley CM**. Neuropsychological support for the concept of white matter dementia. Neurology 2002;53 (Suppl 3):A355-A356.
50. Rollins YD, **Filley CM**, Chalal S, Kleinschmidt-DeMasters BK. Fulminating ascending paralysis as a delayed sequela of Sterno ingestion. J Neuropathol Exp Neurol 2002;61:462.
51. Lafosse JM, Corboy JR, Leehey MA, Seeberger L, **Filley CM**. Neuropsychological support for the concept of white matter dementia. September 26, 2002. [www.cu.edu/ColemanInstitute](http://www.cu.edu/ColemanInstitute).
52. Pelak VS, **Filley CM**, Cutter G. Visual cognition in Alzheimer’s Disease: The Intersecting pentagon Copying task. September 26, 2002. [www.cu.edu/ColemanInstitute](http://www.cu.edu/ColemanInstitute).
53. Arciniegas DB, Topkoff JL, **Filley CM**, Adler LE, Ricketts KA, Spector EB. APOE-ε4 in association with persistent neurocognitive impairment after traumatic brain injury. Am J Hum Genet 2002;71 (Suppl):469.
54. Arciniegas DB, Topkoff JL, **Filley CM**, Adler LE, Anderson CA, Ricketts KA, Spector EB. Apolipoprotein E4 in association with persistent neurophysiologic impairment after mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 2003;15:276.
55. Anderson CA, Bosque PJ, **Filley CM**, Pape J, Tyler KL. Colorado Surveillance Program for chronic wasting disease transmission to humans: two negative cases. Neurology 2003;60 (Suppl 1):A310.
56. Hall DA, Breen J, Bird TD, Schellenberg GD, Leehey M, **Filley CM**. Maternally inherited early-onset dementia with extrapyramidal features, ataxia, and anticipation. Neurology 2003;60 (Suppl 1):A453-A454.
57. Hall DA, Leehey MA, Schellenberg G, **Filley CM**, Bird TD. A prion protein missense mutation in a family with early-onset dementia, neuropsychiatric disorders in childhood and adolescence, and extrapyramidal features. Neurology 2004;62 (Suppl 5):A410-411.
58. Arciniegas DB, Topkoff JL, Anderson CA, **Filley CM**, Adler LE. Frequency of P50 non suppression among individuals with persistent attention and memory complaints following traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004;16:237-238.
59. Mitchell SM, Lafosse JM, **Filley CM**. The nature of verbal memory impairment in multiple sclerosis: a list learning and meta-analytic study. 32nd Annual Meeting of the International Neuropsychological Society, Baltimore, MD, February 7, 2004.
60. Kozora E, Ellison M, Arciniegas D, West S, **Filley C**, Simon J. MRS, MRI and cognitive analyses in Non-NP SLE. 32nd Annual Meeting of the International Neuropsychological Society, Baltimore, MD, February 7, 2004.
61. Anderson CA, Arciniegas DB, **Filley CM**. Treatment of acute ischemic stroke: does it impact neuropsychiatric outcome? J Neuropsychiatry Clin Neurosci 2004;16:223.
62. **Filley CM**. White matter and behavioral neurology. White Matter in the Cognitive Neurosciences: Advances in Diffusion Tensor Imaging and Its Applications Workshop. New York Academy of Sciences, New York, August 20, 2004.
63. Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, **Filley CM**. Rapidly evolving white matter dementia due to lymphomatosis cerebri. Neurology 2005;64 (Suppl 1):A69-A70.
64. Kluger B, Rojas DC, Kronberg E, **Filley CM**. Volitional action as assessed by magnetoencephalography. J Neuropsychiatry Clin Neurosci 2005;17:274-275.
65. Kluger B, Rojas DC, Kronberg E, **Filley CM**. Volitional action as assessed by magnetoencephalography. Clin EEG and Neurosci 2005;36:246.
66. Alderfer BS, Frey KL, Kellermeyer GB, Brousseau K, Topkoff JL, Anderson CA, **Filley CM**, Arciniegas DB. Effect of age on recovery following severe traumatic brain injury. J Neuropsychiatry Clin Neurosci 2005;17:286.
67. Kellermeyer G, Frey K, Alderfer B, Topkoff J, Brousseau K, Anderson CA, **Filley CM**, Arciniegas DB. Frontal dysfunction is a dominant feature of posttraumatic encephalopathy. J Neuropsychiatry Clin Neurosci 2005;17:286.
68. **Filley CM**. White matter disease and cognition. International Workshop on Myelin Imaging, Vancouver, BC, Canada, February 10, 2006.
69. Butler MA, Corboy JR, **Filley CM**. The relationship between psychiatry and neurology from the 1800s to the present and its impact on patient care in multiple sclerosis. J Int Neuropsychol Soc 2006;12(Suppl 1):134.
70. Brousseau K, MaWhinney S, **Filley CM**, Connick E. HIV-associated cognitive impairment: a pilot project to evaluate and improve diagnosis in a university infectious disease clinic. J Neuropsychiatry Clin Neurosci 2006;18:259.
71. Arciniegas DB, Frey K, Alderfer B, Rojas DC, Anderson CA, **Filley CM** Impairments of frontally mediated cognition characterize posttraumatic encephalopathy following resolution of posttraumatic amnesia. J Neuropsychiatry Clin Neurosci 2006;18:281.
72. **Filley CM**, Ramsberger G, Menn L, Wu J, Reid BY, Reid AL. Primary progressive aphasia in a bilingual woman. Neurology 2006;66 (Suppl 2):A205.
73. **Filley CM**, Ramsberger G, Menn L, Wu J, Reid BY, Reid AL. Primary progressive aphasia in a bilingual woman. Colorado Research in Linguistics 2006;19(1).
74. Kleinschmidt-DeMasters BK, **Filley CM**, Rojiani AM. Overlapping features of extrapontine myelinolysis and acquired (non-Wilsonian) hepatocerebral degeneration. Brain Pathol 2006;16 (Suppl 1):S71.
75. Kozora E, Arciniegas D, Brown M, **Filley C**, Miller D, Zhang L, West S. Brain abnormalities in SLE patients with cognitive impairment. American College of Rheumatology Annual Meeting, Washington, DC, 2006:S273.
76. **Filley CM.** Toluene leukoencephalopathy. Neuropsychopharmacology 2006;31 (Suppl 1):S62-S63.
77. **Filley CM**, Ramsberger G, Menn L, Wu J, Reid BY, Reid AL. Primary progressive aphasia in a bilingual woman. October 24, 2006. http://www.colemaninstitute.org
78. Pelak VS, Dubin M, Anderson CA, Arciniegas D, Nakamura T, **Filley C**. Visual perception assessment in Alzheimer’s Disease, mild cognitive impairment, and healthy aging. Hartford/Jahnigen Center of Excellence in Geriatrics Research Forum, Denver, CO, January 18, 2007.
79. **Filley CM,** Rollins YD, Anderson CA, Arciniegas DB, Howard K, Kleinschmidt-Demasters BK. Very early onset Alzheimer’s Disease: is genetic testing mandatory? Hartford/Jahnigen Center of Excellence in Geriatrics Research Forum, Denver, CO, January 18, 2007.
80. **Filley CM**, Ramsberger G, Menn L, Wu J, Reid BY, Reid AL. Primary progressive aphasia in a bilingual woman. Hartford/Jahnigen Center of Excellence in Geriatrics Research Forum, Denver, CO, January 18, 2007.
81. Oster TJ, Wortzel HS, Anderson CA, **Filley CM**, Arciniegas DB. Quetiapine for early posttraumatic mania. J Neuropsychiatry Clin Neurosci 2007;19:214.
82. Wortzel HS, Oster T, **Filley CM**, Anderson CA, Arciniegas DB. Evaluation of suitability of SPECT imaging for use in mild TBI litigation. J Neuropsychiatry Clin Neurosci 2007;19:216.
83. **Filley CM**, Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Kleinschmidt-DeMasters BK. Very early onset Alzheimer’s disease: is genetic testing mandatory? J Neuropsychiatry Clin Neurosci 2007;19:236-237.
84. Brousseau KM, MaWhinney S, **Filley CM**, Connick E. Evaluation of cognitive screening to detect early HIV neurocognitive impairment: a pilot project. J Neuropsychiatry Clin Neurosci 2007;19:233.
85. Brousseau KM, MaWhinney S, **Filley CM**, Connick E. Detection of HIV neurocognitive impairment: screening vs. practice as usual. J Neuropsychiatry Clin Neurosci 2007;19:233-234.
86. Pelak VS, Anderson A, Arcineags D, **Filley C**. A novel scoring method for the intersecting pentagon copying task and its use in autopsy-confirmed Alzheimer’s disease. Neuropsychiatry Clin Neurosci 2007;19:214.
87. Pelak VS, Dubin M, Arciniegas D, Anderson C, Nakamura T, **Filley C.** Visual perception of rotating 3D virtual objects presented in an immersive virtual reality environment in Alzheimer’s Disease, mild cognitive impairment, and normals. Neurology 2007;68 (Suppl 1):A237.
88. Kozora E, Arciniegas D, **Filley C**, Zhang L, Devore MD, Wingrove C, West S. Cognitive function and neurological screening in SLE. Clin Neuropsychol 2007;21:397.
89. Rollins YD, Hudson LA, Anderson CA, Tyler KL, **Filley CM**. Reduplicative paramnesia, myoclonus, and myokymia associated with voltage gated potassium channel antibodies. Ann Neurol 2007;62 (Suppl 11):S57.
90. Kozora E, Arciniegas D, Brown M, Devore MD, **Filley CM**, Grimm A, Miller D, Wingrove C, West S. Relationship between memory impairment and abnormal hippocampal neurometabilites in patients with SLE. Arthritis Rheum 2007;56(9):S220.
91. **Filley CM**, Rollins YD, Anderson CA, Arciniegas DB, Howard KL, Murrell JR, Boyer PJ, Kleinschmidt-DeMasters BK, Ghetti B. The genetics of very early onset Alzheimer’s Disease. October 25, 2007. <http://www.colemaninstitute.org>
92. Kozora E, Arciniegas D, Brown M, **Filley CM**, Miller D, Grimm A, Devore M, Wingrove C, Zhang L, West S. Visual memory impairment in nonNPSLE: relationship to right hippocampal glutamate and glutamine. J Int Neuropsychol Soc 2008;14(Suppl S1):85-86.
93. Brousseau K, Connick E, Kiser JJ, Kaye K, Adler LE, **Filley CM**. Cognitive impairment in the aging HIV-infected patient.  J Neuropsychiatry Clin Neurosci 2008;20:8-9.
94. Howard K, Johnston-Brooks C, Brenner LA, Harwood JEF, Oster TJ, Arciniegas DA, Anderson CA, **Filley CM**. The value of the clock drawing test in the evaluation of Alzheimer’s Disease. J Neuropsychiatry Clin Neurosci 2008;20:9.
95. Kozora E, Maier S, Zhang L, Arciniegas D, Brown M, **Filley C**, Miller D, Grimm A, Devore M, Wingrove C, West S. Anti-NMDA receptor antibodies in nonNPSLE. Brain Behav Immun 2008;22:11.
96. Kozora E, Maier S, Zhang L, Arciniegas D, Brown M, **Filley C**, Miller D, Grimm A, Devore M, Wingrove C, West S. Cytokines, autoantibodies, and cognition in nonNPSLE. Brain Behav Immun 2008;22:11.
97. **Filley C,** Tenenbaum S, Vanotti S, Rao S, Drake M. Neuropsychological aspects of multiple sclerosis in children and adults.J Int Neuropsychol Soc 2008;12(Suppl 2):101.
98. Kozora E, **Filley CM**, Brown M, Miller D, Grimm A, Arciniegas D, West S, Zhang L. Neurometabolic abnormalities associated with cognitive imairment indicate white matter damage in nonNPSLE patients. Arthritis Rheum 2008;58(9):S813.
99. **Filley CM.** Neurologic perspectives on white matter. J Int Neuropsychol Soc 2009;15 (Suppl 1):245.
100. Pelak VS, Dubin M, **Filley C**, Rojas D. Functional MRI of dynamic 3D visual object recognition. Neurology 2009;72(Suppl 3):A331-332.
101. Smyth SF, **Filley CM**, Boyer PJ, Pelak VS. Computerized visual field deficits in posterior cortical atrophy. Neurology 2009:72(Suppl 3):A487.
102. Kenfield MC, Arciniegas DB, Anderson CA, Howard KL, **Filley CM**. When cognitive evaluation does not disclose a neurologic disorder, experience of a university behavioral neurology clinic. J Am Geriatr Soc 2009;59(4 Suppl):S197-S198.
103. Kenfield MC, Arciniegas DB, Anderson CA, Howard KL, **Filley CM**. When cognitive evaluation does not disclose a neurologic disorder, experience of a university behavioral neurology clinic. J Neuropsychiatry Clin Neurosci 2009;12(2):6.
104. Hall DA, **Filley C**, Kluger B, Spector E, Howard K, Zhang W, Tassone F, Hagerman P, Leehey M. Prevalence of *FMR1* gray zone alleles is increased in parkinsonism. Ann Neurol 2009;66 (Suppl 13):S71.
105. Wortzel HS, Kraus MF, Anderson CA, **Filley CM**, Arciniegas DB. Evaluation of the suitability of diffusion tensor imaging for use in mild DTI litigation. J Neuropsychiatry Clin Neurosci 2010;22:245.
106. Hall DA, Kluger B, Spector E, **Filley CM**. Fragile X gray zone expansions are more common than expected in Neurobehavior Clinic patients. Presented at the 12th International Fragile X Conference of the National Fragile X Foundation, July 22, 2010, Detroit, Michigan.
107. Kozora E, Pelzman J, Brown M, Miller D, Arciniegas D, West S, **Filley C**. Information processing speed and white matter abnormalities in non-neuropsycaitric SLE. J Int Neuropsychol Soc 2011;17(Suppl 1):214-215.
108. Kozora E, Pelzman J, Zhang L. Erkan D, Lockshin M, Ulug A, Ramon G, **Filley C,** West S.Comparing cognitive function in non-neuropsycaitric SLE patients from Denver, Colorado and New York, New York. J Int Neuropsychol Soc 2011;17(Suppl 1):320.
109. Pelak VS, Choi M, Jung S, Halliday B, Hager E, Klepitskaya O, Ojemann S, **Filley C**, Dubin M. Visuospatial assessment by virtual 3D radial optic flow illusion in healthy aging, mild Alzheimer’s Disease (AD), and pre-deep brain stimulation (DBS) Parkinson’s Disease (PD) subjects. Abstract A-316-0002-01523. 10th Annual Conference on Alzheimer’s and Parkinson’s Disease. Barcelona, Spain, March 9-13, 2011.
110. Hilger A, Kong APH, Menn L. Yan Y, Ramsberger G, **Filley C**. Longitudinal output changes in a case of logopenic PPA. Procedia Soc Behav Sci 2011;23:31-32.
111. Frederick MC, Sillau S, Arciniegas DB, Anderson CA, Howard KL, **Filley CM.** Differentiation of Alzheimer’s Disease and depression with standard cognitive measures. Ann Neurol 2011;70 (Suppl 15):S29.
112. Kozora E, Ulug A, Erkan D, Ramon G, Vo A, Zimmerman R, Duggan E, Vega J, **Filley C**, Lockshin MD. Cognitive dysfunction and diffusion tensor imaging in systemic lupus erythematosus. Arthritis Rheum 2011;63 (10 Suppl):S544.
113. Kozora E, Erkan D, West SG, **Filley C**, Ulug A, Ramon G, Duggan E, Vega J, Zhang L, Lockshin MD. Cognitive differences in systemic lupus erythematosus patients from the Western (Denver, CO) and Eastern (New York, NY) regions of the United States. Arthritis Rheum 2011;63 (10 Suppl):S902.
114. Grigsby J, Brown MS, Ray M, Onderko A, Royston A, Bennett RE, **Filley CM**. Preliminary magnetic resonance spectroscopy findings among carriers of the fragile X permutation. J Int Neuropsychol Soc 2012;18 (Suppl S1):125.
115. Shipley SM, Kluger BM, **Filley CM**. Accuracy of community-acquired PET scans in the diagnosis of dementia. J Int Neuropsychol Soc 2012;18 (Suppl S1):145-146.
116. Shipley SM, Kluger B, **Filley C**. Accuracy of community-acquired PET scans in the diagnosis of dementia. Neurology 2012;78 (Suppl 1):PD1.010.
117. Hall D, **Filley C**, Shah R, Bennett D, Kluger B, Berry-Kravis E. Frequency of Fragile X gene expansions is Alzheimer Disease and other cognitive disorders. Neurology 2012; 78 (Suppl 1):P05.074.
118. Ghetti B, Murrell J, Boyer P, Piccardo P, Vidal R, Hargrave K, Scott K, Silber M, **Filley C**, DeMasters B, Iyriboz T, Towfighi J.  Early-onset Alzheimer’s Disease associated with PSEN1 L166P mutation: an atypical clinical phenotype. Alzheimers Dement 2012;8:P664-P665.
119. Hua JT, Rojas DC, **Filley CM**, Schwartz RS, Pelak VS.  Structural brain MRI changes following testosterone supplementation in healthy older men. J Investig Med 2013;61:148-149.
120. Kozora E, Arciniegas DB, Duggan E, West S, Brown M, Burleson A**, Filley CM**. PASAT performance and white matter abnormalities in systemic lupus erythematosus (SLE). J Int Neuropsychol Soc 2013;19 (Suppl):226.
121. Burke H, Anderson CA**, Filley CM**. Lasting pain relief after cerebral infarction. American Academy of Neurology 65th Annual Meeting. www.abstracts2view.com.aan/viewalliday V. 2013.
122. Anderson CA, Brega KE, **Filley CM**. Transient prosopagnosia: case report and literature review. J Neuropsychiatry Clin Neurosci 2013:25:2:7.
123. Lonnquist EA, Ringel SP, **Filley CM**. Conversion disorder in frontotemporal dementia. J Neuropsychiatry Clin Neurosci 2013;25:2:9.
124. Grigsby J, Brown MS, Onderko K, Ray M, Bennett RE, Royston A, **Filley CM.** Magnetic resonance spectroscopy and diffusion tensor imaging among male carriers of the *FMR1* premutation. Proceedings of the 1st International Conference on the FMR1 Premutation: Basic Mechanisms and Clinical Involvement. Perugia, Italy, June 2013.
125. **Filley CM**, Brown MS, Onderko K, Ray M, Bennett RE, Grigsby J. White matter disease and cognitive impairment in FMR1 premutation carriers. American Academy of Neurology 66th Annual Meeting April, 2014.AAN.com/view/am14.
126. **Filley CM.** The behavioral neurology of white matter: a new concept. 38th Congress of the Groupe de Recherche sur la Maladie D’Alzheimer (GRAL), « Neurologie Comportementale de la Substance Blanche. » Aix-Marsellie Université, Marseille, France, January 2015.
127. **Filley CM,** Heilman KM, Kertesz A, Denckla MB, Yeo RA. Norman Geschwind and the lasting influence of disconnection. J Int Neuropsychol Soc 2015;21 (Suppl s1):159.
128. **Filley CM**. Disconnection and white matter. J Int Neuropsychol Soc 2015;21(Suppl s1): 160.
129. Hua J, Rojas D, Tregellas J, **Filley C,** Schwartz R, Pelak V. Effects of testosterone supplementation and serum levels on cortical volume in healthy elderly men. American Academy of Neurology 67th Annual Meeting. <http://www.abstracts2view.com/aan/view>, 2015.
130. Persenaire MJ, Holden S, Kluger BM, Woodcock JH, Anderson CA, **Filley CM**. Palliative care: a novel approach to patients with neurodegenerative disease. J Neuropsychiatry Clin Neurosci 2016;28: e57-e58.
131. Kozora E Ulug A, Erkan D, Vo A, **Filley CM**,  Ramon G,  Burleson A, Zimmerman AR, Lockshin M. Functional MRI abnormalities in systemic lupus erythematosus and antiphospholipid antibody positive patients. J Int Neuropsychol Soc 2016;22 (Suppl 1):213.
132. Kozora E Erkan D, Ulug A, Vo A, **Filley CM**,  Ramon G,  Burleson AM, Zimmerman AR, Lockshin MD. Brain abnormalities using diffusion tensor imaging in antiphospholipid antibody-positive patients.  Lupus 2016;25 (1 Suppl):81-82.
133. **Filley CM**, McConnell BV, Anderson CA. The expanding differential diagnosis of toxic leukoencephalopathy. J Neuropsychiatry Clin Neurosci 2017;29:e11.
134. Schubert CL, Alvarez E, Honce JM, **Filley CM**. Use of LesionQuant® to measure cerebral white matter lesion distribution in neuromyelitis optica and relapsing multiple sclerosis. American Academy of Neurology 70th Annual Meeting, Los Angeles, CA, April 2018. <https://submissions.mirasmart.com/AAN2018/itinerary/SearchHome.asp>.
135. Bateman J, **Filley C**, Bettcher B. An exploratory analysis of lifetime surgical history and cognition. American Academy of Neurology 70th Annual Meeting. Los Angeles, CA, April, 2018. <https://submissions.mirasmart.com/AAN2018/itinerary/SearchHome.asp>.
136. Brenner LA, Stearns-Yoder K, Johnston-Brooks C, Hardin KT, **Filley CM**, Kelly JP. Marcus Institute for Brain Health: Selecting and Sharing Outcomes from Evidence-Based Treatments. 4th Interagency Conference on TBI. Washington, DC, June 12, 2018.
137. Johnston-Brooks C, **Filley C**, Kelly J, Hardin K, Sterns-Yoder K, Brenner LA. Marcus Institute for Brain Health: Selecting and Sharing Outcomes to Promote Evidence-Based Treatments. Arch Phys Med Rehabil 2018;99:e140-141.
138. Bateman JR, Rubinstein D, **Filley CM**. Volumetric analysis of mild traumatic brain injury using Neuroquant®. J Neuropsychiatry Clin Neurosci 2018;30:e3.
139. Medina LD, Heffernan KS, **Filley CM**, Bettcher BM. Cognitive and neural correlates of three performance-based functional assessments in normal aging and mild cognitive impairment. Alzheimers Dement 2018;14 (7, Suppl):P297.
140. Bateman JR, **Filley CM**, Ross ED, Bettcher BM, Hubbard HI, Babiak M, Pressman PS. Aprosodia and diminished facial expression with right frontal brain degeneration. J Neuropsychiatry Clin Neurosci 2019;31:e4.
141. **Filley CM**. Social cognition and white matter: a clinical perspective. J Neuropsychiatry Clin Neurosci 2019;31:e10.
142. Otis JB, Campbell JJ, Kaufer DI, Anderson CA, **Filley CM**, Arciniegas DB. Behavioral neurology & neuropsychiatry: a longitudinal perspective on training and education. J Neuropsychiatry Clin Neurosci 2019;31:e22-23.
143. Johnston-Brooks C, Grassmeyer R, **Filley C**, Kelly J. Marcus Institute for Brain Health: two years of clinical experience. J Head Trauma Rehabil 2020;35;E188.
144. Hebert J, Babcock M, Hardin K, Diefenbach H, Milo S, Elliott G, Lucie A, Podkulski J, **Filley C**. Enhancing interdisciplinary care for patients with mild traumatic brain injury (TBI): implementing shared vocabulary to improve outcomes. J Head Trauma Rehabil 2020;35;E179-180.
145. **Utter B**, Anderson A, **Filley C**, Kelly J. Cannabis use trends in a mild traumatic brain injury cohort. J Head Trauma Rehabil 2020;35:E245-E246**.**
146. Kletenik I, Woodcock JH, Churchland PS, **Filley CM**. Morality and the brain: systematic review of lesional causes of immorality. J Neuropsychiatry Clin Neurosci 2020;32:e11-e12.
147. Macchi ZA, **Filley CM**. Prognosis in substance abuse related toxic leukoencephalopathy: a scoping review. J Neuropsychiatry Clin Neurosci 2021;33:250.
148. Elmer AT, Johnston-Brooks C, Bryant VE, Hebert JR, Diefenbach HA, Russel EN, Anderson CA, **Filley CM**, Kelly JP, Arcineigas DB. Factor structure analysis of the Neurobehavioral Symptom Inventory in a Veteran-Predominant cohort with persisting symptoms after mild traumatic brain injury and co-occurring psychological health conditions. J Neuropsychiatry Clin Neurosci 2022;34:282.
149. **Filley CM**. White matter, behavioral neurology, and the influence of corticocentrism. J Neuropsychiatry Clin Neurosci 2022;34:283.
150. Roeske-Anderson L, Elliott G, Carlisle TC, **Filley CM**. Tree drawing analysis in the evaluation of traumatic brain injury: preliminary observations. J Neuropsychiatry Clin Neurosci 2022;34:295.
151. **Filley CM**. Vascular white matter disease and cognition. Rotman Research Institute, University of Toronto, Virtual Conference on Aging & the Brain: The Vascular System and the Aging Brain, March 21, 2023. research.baycrest.org/conference
152. Kletenik I, **Filley CM**, Fox MD, Darby RR. White matter disconnection in acquired criminality. J Neuropsychiatry Clin Neurosci 2023;35:292.
153. Elmer ET, Russel EN, Johnston-Brooks CH, Kelly JP, **Filley CM**, Hebert JR, Arciniegas DB. Defining the minimally important difference on the Neurobehavioral Symptom Inventory among veterans and first responders with chronic mild or moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci 2023:35: 281.
154. Arciniegas DB, Elmer ET, Russell EN, Johnston-Brooks CH, **Filley CM**, Hebert JR, Kelly JP. Efficacy of the integrated practice unit approach on persistent symptoms after mild or moderate traumatic brain injury among veterans and first responders. J Neuropsychiatry Clin Neurosci 2023;35:269-270.
155. Momii AT, Pelak VS, Bettcher BM, Lopez-Panaigua D, **Filley CM**, Holden SK. Cerebral white matter and the Montreal Cognitive Assessment (MoCA) and the Colorado Posterior Questionnaire (CPC-Q). J Neuropsychiatry Clin Neurosci 2023:35;300-301.